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« Celui qui étudie peut poser son regard sur les ombres et les énigmes du monde. Et s‟il étudie 
encore et encore, il commence à comprendre de quoi sont faites ces ombres et ces énigmes, 
c‟est un bonheur inestimable.» 
 
Marek Halter, Le vent des Khazars 
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Résumé  
 
Les microparticules sont des vésicules phospholipidiques de moins d‟un micromètre relâchées 
dans le sang par différents types cellulaires, comme les cellules endothéliales, les plaquettes ou 
encore les globules blancs et rouges. Elles sont bioactives et impliquées dans de nombreux 
processus physiologiques incluant l‟hémostase. De plus, un nombre élevé de microparticules 
circulantes dans le sang a été observé dans différentes pathologies.   
Dans le domaine de la transfusion, les microparticules de globules rouges ont été détectées dans 
les concentrés érythrocytaires. Le but de cette recherche était de caractériser les microparticules 
de globules rouges et d‟évaluer si ces dernières avaient un rôle en transfusion. Pour ce faire, une 
approche globale utilisant différentes techniques comme la cytométrie de flux, la protéomique, la 
microscopie ainsi que des tests d‟hémostase de routines, a été adoptée.  
Le présent travail de thèse a démontré que les microparticules de globules rouges s‟accumulent 
dans les concentrés érythrocytaires pendant le stockage. Leur bioactivité a été démontrée de part 
leur rôle actif dans le processus de la coagulation. En effet, lors de test de génération de 
thrombine, elles peuvent non seulement supporter ce processus de coagulation, mais aussi le 
déclencher par un mécanisme inconnu sous certaines circonstances. Les microparticules de 
globules rouges présentent aussi des antigènes de groupes sanguins à leur surface, toutefois, leur 
implication potentielle dans l‟induction d‟une réponse immunitaire n‟est pas connue. Bien que le 
mécanisme de formation et d‟émissions des microparticules par les globules rouges ne soit pas 
complètement élucidé, il a été démontré qu‟elles n‟ont pas toutes le même contenu protéique et 
donc qu‟elles pourraient avoir des fonctions différentes.        
Au vu des résultats, notamment par leur implication dans la coagulation, il est fort probable que la 
présence de microparticules puisse affecter la qualité des produits sanguins, et causer des 
réactions transfusionnelles.    
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Résumé large public 
 
« Les microparticules de globules rouges : rôle en médecine transfusionnelle ? » 
Olivier Rubin, unité de recherche et développement, Service de Transfusion, Lausanne.   
Les microparticules sont des fragments de cellules d‟un diamètre de 0,1 à 1 micromètre que 
l‟on trouve dans le sang. Elles dérivent des membranes des cellules endothéliales, de 
plaquettes, des globules blancs ou encore de globules rouges. Les microparticules sont 
impliquées dans de nombreux processus physiologiques comme dans la coagulation et une 
élévation de leur nombre dans le sang est liée à différents cas pathologiques.  
Les microparticules de globules rouges sont le principal sujet de cette étude. Le but étant de 
mieux les caractériser en utilisant différentes approches et d‟essayer de déterminer si elles ont 
un rôle en transfusion.   
Dans ce travail, il a été démontré que les microparticules de globule rouges s‟accumulent dans 
les concentrés érythrocytaires pendant leur stockage. Bien que le mécanisme de formation et 
d‟émissions des microparticules par les globules rouges ne soit pas complètement élucidé, il a 
été démontré qu‟elles n‟ont pas toutes le même contenu en protéines et donc qu‟elles 
pourraient avoir des fonctions différentes. Finalement, il a été démontré qu‟elles participent 
activement à la coagulation. Ce dernier point se révèle d‟une importance particulière en 
médecine transfusionnelle. En effet, étant donné que les microparticules de globules rouges 
s‟accumulent pendant le stockage des concentrés érythrocytaire et qu‟elles participent à la 
coagulation, elles pourraient donc être à l‟origine de complications lors de transfusions.     
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Summary 
 
Microparticles are small phospholipid vesicles of less than 1 µm shed in blood flow by 
various types of cells such as endothelial, platelet, white or red blood cells. They are involved 
in many biological and physiological processes including hemostasis. In addition, elevated 
number of microparticles in blood flow is often observed in various pathological situations. In 
transfusion context, erythrocyte-derived microparticles are also found in red blood cell 
concentrates. Their role is not elucidated and they are considered as a part of storage lesions. 
The purpose of this research was to characterize and to accumulate qualitative and 
quantitative data on those erythrocyte-derived microparticles from red cell concentrates. The 
aim was to evaluate their potential impact on blood transfusion. Therefore, a comprehensive 
approach based on four different techniques was employed in this study, namely flow 
cytometry, proteomics, microscopy and hemostasis routine tests. 
This thesis provides evidences that there is release and accumulation of erythrocyte-derived 
microparticles in red cell concentrates during storage. It demonstrates that they are involved 
in coagulation in an active manner and thus are bioactive. Indeed, coagulation assays 
demonstrate that erythrocyte-derived microparticles support and could trigger thrombin 
generation under certain circumstances. Erythrocyte-derived microparticles also bear blood 
group antigens on their surfaces. However, it is not known whether they are able to elicit an 
immune response. Their protein contents vary according to the stimulus suggesting that there 
are different kinds of erythrocyte-derived microparticles that may have different functions.  
Taking together, there is little chance that presence of erythrocyte-derived microparticles in 
erythrocyte concentrates is totally innocuous. In conclusion, these erythrocyte-derived 
microparticles most likely play a role in transfusion medicine and they could cause 
transfusion complications.   
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Abbreviation 
 
CAT   Calibrated Automated Thrombogram 
CTI    Corn Trypsin inhibitor  
EC   Erythrocyte concentrate 
EMPs   Erythrocyte derived Microparticles 
EMPs-TF  TF coated EMPs 
ETP   Endogenous thrombin potential 
FITC   Fluorescein isothiocyanate 
MPs   Microparticles 
PRP   Platelet rich plasma  
PE   Phycoerythrin 
RBC   Red Blood Cell 
TF   Tissue Factor 
TG   Thrombin generation  
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General introduction  
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Introduction  
 
Every year millions of lives are saved thanks to transfusion. With the development of blood 
banks 60 years ago, numerous efforts and progress have been made in order to secure blood 
products. The progress of proteomic techniques allows new perspective in blood research and 
transfusion sciences [1]. 
 
The three main labile blood products are erythrocyte concentrates (ECs), platelet concentrates 
and fresh frozen plasma. Each of those products has to be prepared and stored according to its 
components. Those components are subjected to modifications or degradations during 
storage, a process known as “storage lesion” [2]. 
 
The primary goal of erythrocytes transfusion is to sustain tissues and organs oxygenation, 
principally in case of hemorrhage or acute anemia. The blood bank of Lausanne (SRTS VD) 
relies on approximately 22‟000 active donors allowing preparation of 30‟671 ECs in 2010. 
ECs can be stored up to 42 or 49 days at 4C° in standard SAGM (Salin-Adenine-Glucose-
Mannitol) or PAGGSM (Phosphate-Adenine-Glucose Guanosine-Saline-Mannitol) 
conservative solution. Conditions to which red blood cells (RBCs) are exposed during storage 
such as temperature and nature of the medium are dramatically different from in vivo 
physiological condition. During storage numerous physiological and biochemical alterations 
occur including an increase in the concentration of free hemoglobin, lipids, microparticles 
(MPs) and a pH reduction. RBCs also undergo several changes such as loss of potassium, 
adenosine triphosphate or 2-3-diphosphoglycerate. Their membranes become more rigid, 
there is a disruption of phospholipid asymmetry, lipid rafts rearrangement, loss of fragment or 
even release of MPs [3]. 
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Impact of storage lesion on transfusion efficiency is not clearly understood, and relatively 
little is known about the putative medical consequences on recipient. Several studies have 
shown a link between storage time of blood products and post transfusion complications [4-
6]. However, this is still controversial and some recent studies limited this link only under 
specific circumstances [7-10]. Even if there are no conclusive evidence that longer stored 
blood is worse, it is current practice that some clinical practitioners prefer to transfuse fresh 
blood (such as in neonatology for example). As MPs are bioactive, it could be hypothesized 
that erythrocyte derived MPs (EMPs) are mediators of these complications [11]. Indeed, there 
is a great variability in number of EMPs among ECs, it would be possible thus that a patient 
receive more ECs with elevate number of EMPs. In addition, the elimination rate of MPs is 
also unknown, some people could eliminate more rapidly than others. For these reasons, we 
hypnotized that EMPs could take part to post transfusion complications. Therefore progress in 
the knowledge of stored RBCs biology is urgently needed.  
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Microparticles 
 
Microparticles, also described as microvesicle [12] or ectosomes [13] are plasma membrane 
vesicles shed in blood flow by various types of cells such as platelets, red and white blood 
cells, or endothelial cells[14]. MPs have a size of less than 1 μm. They contain a subset of 
proteins derived from their original cells as well as surface receptors allowing the 
identification of their origin. Most studies generally agree that MPs are heterogeneous and 
vary in size, phospholipids, surface antigens and protein content. Release of MPs is a 
controlled process triggered by various stimuli including pro-apoptotic stimulation, shear 
stress or damage [15].  
 
A model of MPs formation bringing translocases, lipid rafts, various protein modifications 
and irreversible membrane rearrangements has been established [16, 17] (Fig 1). Three 
translocases, namely flippase, foppase and scamblase, maintain phospholipids asymmetry on 
membrane. Negatively charged phospholipids are located on the inner leaflet while neutrally 
charged phospholipids are on the outer leaflet. In cell steady-state, only flippase whose role is 
to specifically translocates negative phospholipids from the outside to the inside membrane 
bilayer is activated. Upon activation, there is elevation of intracellular calcium concentration 
that inhibits flippase, and activates floppase and scramblase. Floppase externalizes negative 
phospholipids (mainly phosphatidylserine) from the inner to the outer leaflet while 
scramblase translocates phospholipids in both way aspecifically. Negatively charged 
phospholipids are thus externalized modifying the neutral membrane charge into negative 
with loss of phospholipids asymmetry.  Calcium also activates proteases in which calpain 
cleaves association between membrane protein and cytoskeleton proteins. There are also lipid 
raft rearrangements and membrane stability being affected, it becomes thus less rigid allowing 
formation and release of MPs [18, 19]. 
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Figure 1: Model of MPs formation. 
A. During cell steady-state, 
maintenance of the asymmetric 
distribution of phospholipids by a three 
piece enzyme system, flippase, 
floppase and scamblase. There is low 
cytoplasmic calcium concentration, 
only flippase that internalize negative 
phospholipids is active.  
 
 
B. Upon activation, intracellular 
calcium concentration increases, 
flippase is inhibited while floppase and 
scamblase are activated. Floppase 
externalize phosphatidyserine, a 
negative phospholipids and scamblase 
translocate phospholipids aspecifically 
through the membrane resulting in the 
loss of phospholipids asymmetry.  
 
C. Increased intracellular 
calcium also activate protease that 
cleave cytoskeleton, membrane is less 
rigid and could bleb until formation 
and release of vesicles.  
 
 
 
If first MPs have been considered as cell fragments or “dust” without any biological function 
[20], there are now recognized as being involved in a broad spectrum of biological activities 
such as thrombosis and hemostasis [14, 21], inflammation [21], vascular and immune 
function burnier [22], transfer of surface proteins or even angiogenesis [15].  
Although the presence of MPs in blood is common in healthy individual, an increase in 
concentration of MPs in plasma has been demonstrated under various pathological conditions 
such as thrombocytopenic disorders [23], thrombosis [14], cardiovascular disease [24], 
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diabetes [25], sickle cell disease [26], haemolytic anaemia [26] or sepsis [27]. Their release 
could be thus considered as a hallmark of cellular alteration. Very low number of MPs has 
been observed in patients presenting with Scott syndrome, a rare bleeding disorder associated 
with apparent normal platelet function and coagulation factor level [28]. 
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Erythrocyte derived microparticles 
 
The main characteristics of EMPs are similar to MPs, as described above. The size of EMPs is 
generally more homogeneous and around 0.15 μm [29] (Fig 2). EMPs represent around 4-8 % 
of total MPs [30] in platelet rich plasma (PRP), these results correspond to our observation. 
As for other MPs, the exact role of EMPs is not elucidated and in the context of transfusion 
they are considered as part of the RBC storage lesions. 
 
Figure 2: Observation of erythrocyte derived microparticles by electron microscopy, 
magnificence 22‟000x 
 
 
EMPs has been describe as a part of RBCs senescence [2] and EMPs formation has been also 
proposed as a part of an apoptosis-like form in erythrocytes [31]. This “aging” process of 
RBCs has also been observed during storage in blood bank condition [32]. During their 120 
days of lifespan, RBCs lose approximately 20% of their volume through vesicles emission 
whereas their hemoglobin concentration increases by 14% [33]. Vesiculation  would be a 
mean for RBCs to get rid of specific harmful agent as denatured hemoglobin, C5b-9 
complement attack complex, band 3 neoantigen, IgG that tend to accumulate in RBCs or on 
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their membranes during their lifespan [3, 32, 34]. In a protective role, by the release of EMPs, 
RBC can clear away those molecules when they are still viable and thus, prevent early 
removal from blood flow. In contrast, EMPs could promote removal of erythrocytes: CD47 is 
an integral membrane protein present on erythrocytes surface, acting as a marker of self. 
Thanks to CD47, normal red blood cells are recognized as self by macrophages (through their 
signal regulatory protein α) and phagocytosis is inhibited. Senescent or damaged red blood 
cells whose CD47 expression is reduced by shedding of EMPs enriched in CD47 would be no 
longer recognized as self and thus be eliminated by macrophages [35]. 
 
Still in the context of RBCs aging process, two main models resulting in microvesiculation 
have been proposed, the eryptosis model and the band 3 clustering.  The term “eryptosis” has 
been introduced a few years ago by F. Lang. It describes a similar mechanism of apoptosis of 
nucleated cells in response to various stresses but for RBCs [31] (Fig 3). Influx of ionic 
calcium through nonspecific cation channel leads to activation of several enzymes such as 
calpain or scramblase. Reasons triggering this calcium intake are largely unknown but 
alteration of nonspecific cation channels is often mentioned as a possible cause [36, 37]. The 
band 3 clustering model is characterized by protein oxidation. The oxidation of Hb 
contributes to hemichrome formation, which is constituted Hb derived products (likely met-
Hb) linked to the inner leaflet, followed by the clustering and aggregation of band 3 
multimers in the membrane [38]. Band 3 clustering forms or uncovers senescent neoantigens, 
probably because of relatively small structural modifications that are recognized by naturally 
occurring autologous IgG with subsequent complement activation [39]. 
Both models share final outcome, there are phosphatidylserine externalization on RBCs 
membrane, degradation of cytoskeleton proteins followed by modification in the 
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phosphorylation status of band 3. This process gives sufficient membrane flexibility resulting 
in EMPs formation and release.      
 
Figure 3: Pathways leading to eryptosis 
PLA2 : phospholipase A2 
COX : cyclooxygenase 
PGH2 : Prostaglandin H2 
PGE2 : Prostaglandin E2 
NS cation channel : Non 
specific cation channel 
NEM : N-
Ethylmaleimide   
 20 
Erythrocyte derived microparticles and transfusion  
 
During their period of conservation at 4°C prior to transfusion, storage lesion in ECs occurs 
resulting in modification, alteration or even degradation of various components [1, 2]. RBCs 
ageing in blood bank conditions clearly differ from physiological in vivo. Undeniably, 
temperature or medium in which RBCs are conserved dramatically differ from in vivo 
conditions and cause degradation or loose of efficiency of RBCs. Indeed, erythrocytes change 
shape from biconcave disk to rigid spheroechinocytes [40] conducting to disruption of 
phospholipids asymmetry and release of fragments and EMPs [2]. In addition, during the 
conservation of erythrocyte in plastic bags, not only physiological alterations occur, but also 
biochemical changes in the storage medium principally due to red cells metabolism. There is 
an increase in the concentration of lipids, free haemoglobin, potassium, lactate and in contrast 
a reduction of pH, glucose, 2,3-diphosphoglycerate, sodium or adenosine triphosphate [41]. 
For example diminution of glucose and increase of lactate concentration reflects red blood 
cells glycolysis. Those changes due to storage affect RBCs deformability, osmotic resistance 
and survival after transfusion [42]. In circulating blood, EMPs are rapidly removed in the 
liver by Kupffer cells [33]. Release of EMPs occurs throughout erythrocyte lifespan and 
continues during storage; consequently, the very large majority of MPs originate from RBCs 
and their number gradually increases with storage time [29].   
 
The precise consequences of storage, including EMPs accumulation in ECs, on transfusion 
efficiency are not understood, and relatively little is known about their possible biomedical 
consequences on recipients. There are accumulating evidences that receiving “older” blood is 
not as advantageous as receiving fresher blood. In 2008, Koch et al showed a link between the 
age of the transfused ECs and post-transfusion complications. They claimed that life 
expectancy at 5 years was better for patients who received fresher blood (ECs stored for less 
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than 14 days) as compared to older blood (stored for more than 14 days) in the course of 
cardiac surgery [4]. A study by Spinella et al concluded that ECs stored for more than 28 days 
was associated with an increased incidence of deep vein thrombosis and death from multi-
organ failure [9]. Other studies on post-transfusion complications or mortality and storage 
time were also published and controversial [43-45]. However, although these studies raise 
important questions about transfusion safety and storage lesions, they are subjected to many 
discussions [46-48]. Due to the fact that transfused people are sick and polytransfused 
recipients are often in poor condition, it is difficult to attribute clearly an event to transfusion 
rather than on the clinical situation of the recipient. In a recent review, Zimrin and Hess 
analyzed several papers on clinical studies examining the effect of storage of red blood cells 
in transfusion and concluded that well designed epidemiologic studies are needed to 
demonstrate that a clear clinical effect may be due to ECs storage lesions [49]. Despite the 
lack of conclusive evidence that storing blood longer is worse, it is current practice to 
transfuse fresher blood to patient considered at high risk (such as in neonatology for example 
or cardiac surgery) and to put blood banks under pressure to prioritize delivery of fresher ECs. 
Blood banks are in an uncomfortable situation due to the fact that there are few arguments to 
evaluate the safety and efficacy of older products compared to fresher one. 
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Microparticles and coagulation  
 
Blood coagulation is an essential mechanism that prevents bleeding; this highly controlled 
process is carefully regulated in order to maintain blood circulation in case of injury while 
preventing vessels obstruction by clot formation. Coagulation factors, calcium ions and 
procoagulant membrane surfaces are the primary components involved in coagulation 
activation. The presence of negatively charged phospholipid membranes and calcium ions is 
required for the assembly of coagulation complexes such as tenase or prothrombinase. The 
role of tenase complex is to convert factor X into activated factor X, in both extrinsic and 
intrinsic pathways. The extrinsic tenase complex is composed of tissue factor (TF) and 
activated factor VIIa [50] whereas the intrinsic tenase is composed of co-factor VIII and 
activated factor IX [51, 52]. The function of prothrombinase, constituted of activated co-
factor V and activated factor X, is to convert prothrombin into thrombin. Activated factors IX 
and X can convert their substrate without their respective cofactors, however negatively 
charged membranes catalyses the reaction, for example 3x10
5
 fold faster in the case of 
prothrombinase [53 ]. The importance of negative phospholipids is to facilitate complex 
association, speeding up their association by around 1000 fold for efficient haemostasis [54]. 
As MPs expose negative membrane, they could contribute to coagulation (Fig 4). It has been 
demonstrated that platelets-derived MPs have from 50- up to 100-times more procoagulant 
activity than platelets [55]. MPs membranes support more efficiently thrombin formation than 
platelet membrane when corrected for unit of surface, at least in vitro [16, 52]. As they 
present negatively charged membrane as well, EMPs or other MPs could be involved in this 
process [26, 56]. 
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Figure 4: Scheme of the coagulation cascade showing at what level microparticles participate 
 
Although controversial, some authors claim that MPs support clotting not only through their 
negatively charged membranes, but also by expressing an inactive form of tissue factor (TF) 
on their surfaces. The origin and mechanism of action of blood-born TF is still subject to 
debate, nevertheless authors have suggested that MPs may be a reservoir of blood-born 
TF[57]. Furie et al delineated a “microparticles accumulation pathway” as part of the 
coagulation cascade [52]. According to this model, some monocyte-derived MPs expressing 
TF in an “inactive” form bind to a forming clot in vessels and display active TF that helps to 
amplify coagulation. In an other hand, Connor et al proposed an activated factor X assay to 
measure clotting time of various samples containing MPs and their results show that there is a 
correlation between the number of MPs and clotting time; interestingly enough, the assay was 
insensitive to the presence or the absence of TF [58]. Other studies mention the presence of 
TF on endothelial-derived MPs [59], platelet-derived MPs [60], or even on erythrocyte-
derived MPs [30] , while some others did not detect any MPs-exposing TF [26]. All these 
pieces of evidence are difficult to explain, in particular because results often depend on the 
study design, methods of MPs isolation, and various pre-analytical factors; therefore one 
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cannot exclude that discrepancies might result from different experimental methodologies 
[61]. 
As stated before, MPs may have procoagulant activities; therefore, we may reasonably 
suggest that transfusion of “older” ECs containing a higher number of MPs could increase the 
risk of adverse reactions, by inducing a hypercoagulable state leading to thromboembolic 
complications. Inversely, in many situations requiring blood transfusion, a hypercoagulable 
state may be useful to diminish or even helping to stop the bleeding. 
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Outline of this thesis  
 
 
As there is little data on EMPs, the main goal of this thesis was to characterize EMPs from 
ECs and to evaluate if they have a role in transfusion medicine. As mentioned above, MPs are 
bioactive and involved in various pathophysiological processes and their presence has been 
demonstrated in blood product. There is thus little chance that their presence is totally 
innocuous. Therefore, a comprehensive approach based on four different techniques has been 
employed in this study, namely flow cytometry, proteomics, imaging and hemostasis routine 
tests (Fig 5). 
 
An extensive overview of the current knowledge on MPs from RBCs and their putative 
implication in transfusion medicine are introduced in Chapter 2. In order to obtain better 
characterization of EMPs, qualitative and quantitative experiments conducted on EMPs from 
stored ECs by various methods are presented in Chapter 3. Chapter 4 highlights the 
importance of pre-analytical factors and their impacts. There is also a discussion on various 
methodological aspects of experiments on EMPs. Implications of EMPs in coagulation and 
the putative side effect on transfusion role are discussed in Chapter 5. Experiments 
concerning the participation of EMPs to coagulation (or thrombin generation) using 
Calibrated Automated Thrombogram are presented in Chapter 6. Finally, ethical 
considerations on blood donation are discussed in chapter 7 (in French). 
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Figure 5: General schema of experimental approach on erythrocyte derived microparticles 
during the thesis (adapted from Rubin et al) [62].   
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Abstract  
 
Purpose of review 
The mechanisms involved in the formation of red blood cell (RBC) microparticles in vivo as 
well as during erythrocyte storage are reviewed, and the potential role of microparticles in 
transfusion medicine is described. 
 
Recent ﬁndings 
Microparticles release is an integral part of the erythrocyte ageing process, preventing early 
removal of RBCs. Proteomics analyses have outlined the key role of band 3–ankyrin 
anchoring complex and the occurrence of selective RBC membrane remodeling mechanisms 
in microparticles formation. The presence of several RBC antigens, expressed on 
microparticles, has been demonstrated. The potential deleterious effects of RBC 
microparticles in transfused recipients, including hypercoagulability, microcirculation 
impairment and immunosuppression, are discussed. 
 
Summary 
Formation and role of RBC microparticles are far from being completely understood. 
Combining various approaches to elucidate these mechanisms could improve blood product 
quality and transfusion safety. Implementation of RBC microparticles as biomarkers in the 
laboratory routine needs to overcome technical barriers involved in their analysis. 
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Introduction  
 
Microparticles, also described as microvesicles [1] or ectosomes [2], are heterogeneous 
populations of phospholipid vesicles of less than 1 mm, released in circulating blood by 
erythrocytes, platelets, white blood cells or endothelial cells [3]. The production of 
microparticles is a highly controlled process, triggered by various stimuli, including cell 
stimulation and apoptosis [4]. If microparticles have been ﬁrst described as cell dusts [5], they 
are now recognized as being involved in a broad spectrum of biological activities, such as 
thrombosis and haemostasis [3,6], inﬂammation [6], vascular and immunefunction [7], 
apoptosis [4] or even intercellular communication by the transfer of surface proteins [8]. 
Microparticles are detected in healthy individuals and their increase has been observed in a 
variety of diseases with elevated thrombotic risk, vascular involvement or metastasis 
[9,10,11].Proteomics analysis has been recently applied to the study of red blood cell (RBC) 
microparticles (reviewed in [12]) and allows identiﬁcation of numerous different proteins in 
biological samples. Proteomics has been successfully used in the ﬁeld of transfusion medicine 
[13–15] and allowed the deciphering of various blood diseases [16]. Nevertheless, and 
whatever methods are employed to characterize microparticles, preanalytical issues remain of 
major importance to correctly assess microparticles in blood [17]. The lack of standardized 
methods has impaired microparticles analysis implementation in the clinical setting [18]. 
 
Formation and clearance of red blood cell microparticles 
 
The normal erythrocyte has a unique membrane and cytoskeleton organization with redundant 
surface area and sufﬁcient ﬂexibility to undergo extensive deformation during its transit 
through the spleen [19]. Under physiological conditions, the asymmetric distribution of RBC 
membrane phospholipids is maintained by the cooperative action of translocases (ﬂippase, 
ﬂoppase and scramblase), concentrating negatively charged aminophospholipids, like 
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phosphatidylserine on its inner leaﬂet[20]. 
 
 
Microvesiculation 
Rapid externalization of phosphatidylserine after cell activation or apoptosis modiﬁes the 
neutral membrane charge into negative with loss of phospholipid asymmetry, leading to a 
cascade of events which disrupts the interactions between membrane and cytoskeleton 
proteins, speciﬁcally spectrin and protein 4.1R. The stability of the membrane is thus directly 
affected, becoming less rigid and allowing the formation and release of microparticles 
[21,22]. During their lifespan, RBCs lose approximately 20% of their haemoglobin (Hb) 
content, and similar surface area through vesicles emission, thus decreasing their favourable 
surface-to-volume ratio [23]. Microvesiculation occurs throughout the erythrocyte lifespan 
and is triggered by different types of stimuli [23], such as shear stress, complement, attack,n 
oxidative stress and pro-apototic stimulations [4]. As shown during complement activation, 
microvesiculation prevents immediate killing of RBCs by eliminating the membrane attack 
complex C5b–9; this survival strategy is especially used when expression of complement 
regulatory proteins on the cell surface are decreased [24]. It remains obscure how the spleen 
facilitates microparticles formation during the second half of the erythrocyte lifespan; 
interestingly, improvement of RBC osmotic fragility due to increase of surface area has been 
described in patients with hereditary spherocytosis after splenectomy [25,26]. 
 
Erythrocyte ageing models 
Microparticles formation has been described as an inte-gral step of RBC senescence [23]. 
Two major models of erythrocyte ageing have been proposed so far: the eryptosis and the 
band 3 clustering. The eryptosis model, which is similar to apoptosis of nucleated cells, could 
be regarded as the RBC response to various stresses, whereasmthe band 3 model may explain 
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the physiology of RBC ageing [27]. In the eryptosis model, intracellular ﬂux of calcium 
through possibly altered nonspeciﬁc cation channels leads to activation of several enzymes, 
such as scramblases, calpains and transglutaminase 2. This results in phosphatidylserine 
externalization, degradation and cross-linking of cytoskeletal proteins, followed by 
modiﬁcations in the phosphorylation status of band 3 [28,29,30]. The band 3 clustering model 
is characterized by protein oxidation [31]. The oxidation of Hb contributes to hemichrome 
formation, which is constituted Hb-derived products (likely met-Hb) linked to the inner 
leaﬂet, followed by the clustering and aggregation of band 3 multimers in the membrane [32]. 
Band 3 clustering forms or uncovers senescent neoantigens, probably because of relatively 
small structural modiﬁcations that are recognized by naturally occurring autologous IgG with 
subsequent complement activation [33–35]. Both models share the similar ﬁnal outcome that 
leads to modiﬁcations of band 3 and induces perturbations of the inner leaﬂet 
microenvironment, which could alter the tight balance between the membrane and 
cytoskeleton forces, thus resulting in microvesiculation. It has been shown that modiﬁcations 
of the band 3–ankyrin anchoring complexes could enhance lateral compression forces of the 
cytoskeleton, making the RBC membrane prone to distortion. Thereby, band 3 anion 
exchanger should be considered as a key protein in the regulation of erythrocyte structure and 
function [23], through binding cytoskeleton proteins, glycolytic enzymes and Hb [36]. 
 
Microparticles composition 
Reviews of proteomic analysis of microparticles have been published elsewhere 
[17,37,38,39]. The composition of RBC microparticles may vary according to the stimulus 
and differs from their parental cell by nearly complete absence of cytoskeletal-linked 
molecules, decrease of membrane proteins content, presence of more metabolic proteins and 
Hb and exposure of removal signal molecules such as phosphatidylserine and autologous IgG 
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[23,40]. Furthermore, enrichment of several erythrocyte membrane components has been 
described, especially band 3, glycophorins, complement receptors, glycosyl-
phosphatidylinositol (GPI)-anchored proteins and lipid-raft markers, suggesting selective 
membrane lipids and protein sorting. In lipid-raft origin of RBC microparticles, the oxidation 
of cytoskeleton proteins may promote lateral movement of stomatin oligomers in the 
membrane, which serve as nuclei for lipid-raft aggregation and extension, leading to the 
budding of membrane lipid-patches detached from cytoskeleton and segregation of molecules, 
including stomatin and GPI-anchored proteins [39,41]. 
 
Clearance mechanisms 
Once generated in circulating blood, phosphatidylserine exposing RBC microparticles are 
rapidly and efﬁciently removed by binding to the macrophage‟s scavenger receptors of the 
organ in which they originate [40]. Alternatively, RBC microparticles carrying senescent 
neoantigen-speciﬁc autoantibodies are recognized by Fcg-receptors and eliminated through 
the mononuclear phagocyte system [42]. According to the limited capacity of RBCs for self-
repair, vesicles formation, which is an ATP-free mechanism even faster than translocation 
back of phosphatidylserine [40], may not only help to remove membrane-damaged molecules, 
postponing the phagocytosis of otherwise functional erythrocytes, but also prevents the 
exposure of potentially dangerous molecules [39]. Once microvesiculation capacity is 
exceeded, old erythrocytes are most likely phagocytosed. 
 
Red blood cell microparticles and transfusion medicine 
 
Under blood bank conditions, RBCs undergo progressive structural and biochemical changes 
commonly referred to as „the storage lesion‟ [39]. As shown in Fig. 1, erythrocytes show 
progressive cell shape transformation from biconcave disk to rigid spheroechinocyte [42], 
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accompanied by the release of microparticles from the tips of spicules [6,43]. In addition, 
there is a depletion of ATP, pH acidiﬁcation, haemolysis and microparticles accumulation 
observed in the medium [41]. Although differences have been reported between in-vitro and 
in-vivo RBC senescence such as denaturation of spectrin, changes in carbohydrate part of the 
membrane and increased mean cellular volume, the storage lesion shares similar features with 
the cell ageing process [38,44]. RBC membranemodiﬁcation during storage is triggered by 
ATP depletion and oxidation and is centred on changes in band 3 leading to membrane 
detachment and disorganization that probably affect RBC deformability, osmotic resistance 
and survival after transfusion [45,46]. 
 
Figure 1: Observations of microparticles by microscopy give information about their size and 
shape 
 
By confocal differential interference contrast 
microscopy, it is possible to observe forming 
microparticles (arrows) from spicules of 
echinocytes (magnification 4000 x) 
 
 
 
 
 
 
Microparticles in erythrocyte concentrates 
 
RBC microparticles formation represents a continuousprocess of membrane remodelling, 
which occurs early during blood banking [41,47], and prevents the exposure of 
phosphatidylserine on RBC [48]. Almost all microparticles found in erythrocyte concentrates 
originate from RBCs and their number gradually increases with storage time [37,42,49]. The 
level of vesiculation in erythrocyte concentrates may vary not only with the length of storage 
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but also according to the product and the storage solution: RBC microparticles are increased 
in washed blood products [50,51], whereas they could be lowered with additive solutions that 
manage effectively the oxidative stress [44]. The level of circulating microparticles could 
signiﬁcantly increase, as already observed in transfusedpatients presenting with paroxysmal 
nocturnal haemoglobinuria [50]. 
 
The composition of RBC microparticles in erythrocyte concentrates is nearly similar to those 
generated in vivo, except for the increased levels of stomatin, making it likely that a raft-
based process is responsible for microvesiculation at low temperatures [41]. As those 
generated in vivo, the vesicles found in erythrocyte concentrates are devoid of most of the 
RBC integral membrane proteins or cytoskeletal components, with the exception of actin and 
band 3, found in aggregated or degraded forms [6,39,41]. Proteomics data conﬁrm exposure 
of phosphatidylserine, binding of immunoglobulins and partial activation of complement on 
their surface. The signiﬁcant difference observed in membrane composition between RBCs 
and microparticles outline that vesicles are generated by speciﬁc processes, which allow 
sorting of lipids and proteins [39]. Nonetheless, the pathways responsible for membrane lipids 
remodelling before microvesiculation remain mostly unknown. According to the absence of 
immunologic removal, microparticles in erythrocyte con- centrates become more 
heterogeneous over time with a gradual increase of their size and of their content of 
proteasome components, and a decrease of phosphatidylserine exposure [38,42], suggesting 
that either microparticles structure or nature of vesicle formation may vary with storage time. 
 
Microparticles and blood group antigens 
Half of the RBC transmembrane proteins carry various blood group antigen speciﬁcities [52]. 
Some of them, such as the rhesus (Rh) proteins, contribute to membrane stabilization through 
their link with protein 4.1R [53]. Blood storage is associated with the generation of soluble 
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ABH antigens in the bag, parallel to the decrease of their expression on erythrocytes [54]. 
Various studies have shown that blood group antigens are located on microparticles [55,56]. 
The identiﬁcation of Rh peptides by mass spectrometry and Rh antigens by ﬂow cytometry 
(Fig. 2) indicates that the protein is present within the membrane and that the antigenic part is 
located at the outer side of the microparticles membrane [37]. Our ﬂow cytometry analyses 
demonstrated the presence of several antigens such as RH2 on microparticles (Fig. 2) as well 
as RH1, RH3, RH4, RH5, FY1, FY2, JK1, JK2 and KEL1 (data not shown). Despite their 
cytoskeletal dissociation, Rh antigens on microparticles keep the property to react with the 
corresponding antibodies. However, it is not known whether they are able to elicit an immune 
response. Another striking feature is the suppression of RBC antigens during autoimmune 
haemolytic anemia and during transfusion of incompatible blood [57,58]. It has been reported 
that antibody binding could induce disruption of membrane organization as well as vesicle 
formation with consequently the loss of the corresponding blood group antigens [59]. The 
exact mechanism of antibody-induced antigen suppression, which allows transfused RBC to 
escape haemolysis, is not known but it is tempting to speculate that selective loss of antigen 
might occur through RBC vesiculation. 
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Figure 2: General scheme presenting the most used analysis methods of microparticles 
 
 
The upper left corner of the ﬁgure shows part of a red blood cell and microparticles (scanning 
electron microscopy; magniﬁcation, Â37 000). By ﬂow cytometry technique, it is possible to 
sort microparticles from erythrocytes according to size and shape. Panels (A) and (B) show 
the region of microparticles sorted according to their ﬂuorescence. Microparticles issued from 
a RH:2,-4 typed erythrocyte concentrate were tagged by RH2 antibodies (B), but not with 
RH4 antibodies used as negative control (A) (tagged microparticles are on right and 
nontagged on the left) (adapted from [37]). Microparticles were double labelled with anti-
CD235a (glycophorin A) which binds to the vast majority of erythrocyte microparticles 
(histograms show „MP region‟ according to their ﬂuorescence; the tagged microparticles are 
on the right and nontagged on the left of panel A and B). Flow cytometry analysis also may 
reveal other red blood cell antigens on microparticles (such as Duffy or Kell). Microparticles 
proteins can be separated by different techniques such as SDS-PAGE (one-dimensional gel 
electrophoresis) or two-dimensional gel electrophoresis combined either with image analysis 
or mass spectrometry. Using this approach, various microparticles proteins were identiﬁed. Of 
note, two-dimensional gel electrophoresis of microparticles is hampered by the presence of 
large amounts of haemoglobin, which can be removed by off-gel electrophoresis, allowing a 
resolution sufﬁcient for comparison image analysis. GE, gel electophoresis. Adapted with 
permission from Rubin et al. [12]. 
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Clinical relevance 
A large proportion of Hb is enclosed in RBC microparticles [60,61] and, with free Hb, 
participates in the increase of extracellular Hb during storage. Hb composition of 
microparticles resembles that of the oldest RBC and is enriched in denatured and high 
molecular weight fractions [39,42]. Due to their small size and the lack of most of the 
cytoskeletal proteins, it is expected that RBC microparticles could localize near the 
endothelium and will probably scavenge nitric oxide as effectively as cell- free Hb [62,63]. 
This reduction of nitric oxide bioavailability will affect adversely the microcirculation by 
promoting platelet aggregation and endothelial adhesion, impairing vasodilatation and 
generating reactive oxygen species [60]. 
 
Moreover, phosphatidylserine exposure on RBC microparticles surface offers a binding site 
for prothrombinase and tenase enzyme complexes [12,64] and is associated with increased 
activity of factors VIII, IX and XI [65], thus participating in thrombin generation and 
ampliﬁcation. Hypercoagulable state associated with enhanced microparticles levels has been 
observed in chronic haemolytic anemia, including in sickle cell patients [65,66]. Although the 
relationship between RBC microparticles concentration and increased risk of arterial or 
venous thrombosis events after blood transfusion is not evident, this question has been raised 
recently in cancer patients [67]. 
 
The RBC microparticle potential role of cell-to-cell communication has not been investigated 
so far. RBC microparticles, as other cell-derived microparticles, could transfer molecules and 
modify cell phenotype such as illustrated by the transfer of GPI-anchored proteins CD55 and 
CD59 from vesicles found in erythrocyte concentrates to erythrocytes and granulocytes of 
paroxysmal nocturnal haemoglobinuria transfused recipients [50]. Moreover, the recruitment 
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of RBC microparticles by nucleated cells allows the transfer of removal signals such as 
phosphatidylserine to innocent bystanders [68], labelling them with an apoptosis marker. 
These data offer a perspective of further investigations in the ﬁeld of cell-to- cell 
communication capacity of RBC microparticles. 
 
In addition to activating the classical complement pathway through IgG on their membrane, 
storage vesicles may affect the innate immune response by inhibiting the production of pro 
inﬂammatory cytokines such as tumour necrosis factor-a and interleukin-8 [49]. To what 
extent this anti-inﬂammatory signal may explain some of the immunosuppressive effects of 
blood transfusions remains to be clariﬁed. 
 
Although vesiculation contributes to erythrocyte homeostasis in eliminating sorted oxidized 
proteins [42], theimpact of RBC microparticles on the microcirculation coupled with their 
immunomodulation and thrombogenic activities could potentiate adverse clinical outcomes 
observed in susceptible recipients transfused with older blood [69,70]. Undeniably, these 
observations raise important questions about the clinical impact of RBC storage lesions; 
however, this topic remains a matter of debate and needs strong epidemiologic data to clarify 
its role in transfusion medicine. 
 
Conclusion 
 
Extensive proteomic analyses of RBC microparticles have enabled a better comprehension of 
erythrocyte changes during ageing and blood storage and outlined the pivotal role of band 3–
ankyrin anchoring complex. Indisputably, vesicle formation represents an integral part of the 
erythrocyte ageing process. RBC microparticles could be considered as the „Dr Jekyll and Mr 
Hyde‟ in the ﬁeld of transfusion: on one hand, improving RBC survival in transfused 
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recipients by allowing the elimination of toxic molecules and removal signals; on the other 
hand, enhancing the deleterious events like microcirculation impairment, thrombosis and 
immunosuppression in susceptible patients. 
 
Despite the currently available proteomics and immunochemical data, the exact and complete 
mechanisms of erythrocyte microvesiculation remain only partially elucidated. Combining 
comparative and qualitative proteomic analysis with other different approaches including 
immunochemical data or ﬂow cytometry will help to discover the precise components 
involved in RBC microparticles formation and may identify the potential role of 
microvesicles in transfusion medicine. Therefore, proteomic analysis will provide a tool for 
the development of methods that could enhance RBC quality and survival after transfusion. 
Nevertheless, the use of microparticles as biomarkers in clinical routine or blood banking 
needs the technical barriers involved in their analysis to be overcome. 
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Abstract 
 
Background and Objectives  
Microparticles (MPs) are small phospholipid vesicles of less than 1 µm, shed in blood ﬂow by 
various cell types. These MPs are involved in several biological processes and diseases. MPs 
have also been detected in blood products; however, their role in transfused patients is 
unknown. The purpose of this study was to characterize those MPs in blood bank conditions. 
 
Materials and Methods  
Qualitative and quantitative experiments using ﬂow cytometry or proteomic techniques were 
performed on MPs derived from erythrocytes concentrates. In order to count MPs, they were 
either isolated by various centrifugation procedures or counted directly in erythrocyte 
concentrates. 
 
Results 
A 20-fold increase after 50 days of storage at 4°C was observed (from 3370 ± 1180 MPs/µl at 
day 5 to 64 850 ± 37 800 MPs/µl at day 50). Proteomic analysis revealed changes of protein 
expression comparing MPs to erythrocyte membranes. Finally, the expression of Rh blood 
group antigens was shown on MPs generated during erythrocyte storage. 
 
Conclusions 
Our work provides evidence that storage of red blood cell is associated  with the generation of 
MPs characterized by particular proteomic proﬁles. These results contribute to fundamental 
knowledge of transfused blood products. 
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Introduction 
 
Millions of blood products are transfused worldwide every year; many lives are thus directly 
concerned by transfusion. Since the beginning of blood transfusion, numerous efforts have 
been made to secure blood products and gain knowledge about their molecular structures. The 
progress of proteomics allows re-examining important issues in blood research [1] and 
transfusion science [2] with the tools of large-scale biology [3].  
The three main labile blood products used in transfusion are erythrocyte concentrates (ECs), 
platelet concentrates and fresh-frozen plasma. Each of these products has to be stored 
according to its particular components. However, during storage, modiﬁcation or degradation 
of those components may occur and are known as storage lesions. Among these lesions, the 
generation of microparticles (MPs) has been identiﬁed [4–6]. 
Ageing erythrocytes in blood bank conditions differ from in vivo, therefore, it has been 
suggested that erythrocyte physiological ageing process may be accelerated by storage 
conditions [7]. Indeed, during storage, several biochemical and physiological changes occur 
in ECs, including an increase in the concentration of free haemoglobin, lipids, MPs and a pH 
reduction. Concerning red blood cells (RBCs), they lose adenosine triphosphate, 2,3-
diphosphoglycerate or potassium and their membrane undergoes various modiﬁcations, such 
as more rigidity, disruption of phospholipids asymmetry, protein clustering, lipid raft 
rearrangement, loss of fragments or even release of MPs [8–10]. The exact effects 
of storage lesions on transfusion are still unknown. 
Microparticles are small phospholipid vesicles of less than 1 µm in size, also known as 
microvesicles [11] or ectosomes [12]. They are released from a variety of cells, such as 
platelets, RBCs and white blood cells, or endothelial cells [13]. They contain a subset of 
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proteins derived from their parent cells. However, MPs are heterogeneous and vary in size, 
phospholipid and protein composition. Release of MPs is a highly controlled process prompted by 
various stimuli, such as shear stress, complement attack, proapoptotic stimulation or damage [14]. 
Microparticles have long been considered as cell fragments or „debris‟ without any biological 
function. Although their true biological function is still unknown, there are more and more 
indirect evidence that MPs are involved in a broad spectrum of biological activities, such as 
haemostasis [15], thrombosis [13], inﬂammation [15], transfer of surface proteins [16] or even 
angiogenesis [17]. 
An increase in the number of MPs in plasma has been demonstrated under various pathological 
conditions, such as heparin-induced thrombocytopenia [18], thrombotic thrombocytopenic 
purpura [19], diabetes [20,21], acute coronary syndromes [22], cardio vascular disease [23] or 
sepsis [24]. Despite their potential important activities, only few studies are available on MPs in 
blood products. It has been demon- strated that the number of MPs increases with the age of blood 
products [25] and that there is a link between the risk of transfusion complication and the age of 
the transfused blood products [26,27]. Thus, an appealing hypothesis is that a high number of 
MPs in ECs is linked to adverse transfusion reactions. In addition, Koch et al. recently 
demonstrated a link between the age of transfused RBCs and post-transfusion complications [28], 
indicating that progress in the knowledge of stored RBCs biology is urgently needed. In order to 
have a better understanding of MPs in stored ECs, qualitative and quantitative experiments using 
ﬂow cytometry or proteomic techniques were developed and performed. The goals of this study 
were: (i) to test centrifugation methods for the isolation of MPs from ECs; (ii) to count MPs 
directly in ECs and in their supernatant fraction; and (iii) to gain insight into the protein content of 
MPs as compared to RBC membranes, and (iv) to evaluate if erythrocyte-derived MPs also 
express Rhesus antigens on their surface. 
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Materials and methods 
Erythrocyte concentrates 
Whole blood was collected and prepared at the Lausanne or Bern blood banks, according to 
standardized procedures. Only ECs that did not satisfy quality criteria for transfusion were 
used for this study, notably those collected from donors presenting with elevated levels of 
alanine transaminases (ALAT). Brieﬂy, 450 ± 50 ml of whole blood was drawn by 
venipuncture and collected in blood bags (Fenwal, Lake Zurich, IL, USA) containing the 
anticoagulant solution (citrate–phosphate–dextrose). Leucocytes and platelets were then 
removed by ﬁltration. After separation of plasma from erythrocytes by centrifugation, RBCs 
were ﬁnally suspended in 100 ml of preservative solution sodium–adenine–glucose– 
mannitol. For the experimental purpose of this study, ECs were stored up to 50 days at 4°C 
instead of 42 days, the usual expiration date for concentrates in sodium–adenine– glucose–
mannitol solution. 
 
Flow cytometry analysis and microparticles counts in erythrocyte concentrates 
Samples were analysed on a FACScalibur ﬂow cytometer with CellQuest pro software (BD 
Biosciences, Franklin Lakes, NJ, USA). Flow cytometer was daily calibrated with 
CaliBRIT™ 3 kit (BD Biosciences) containing different ﬂuorescent beads. Size events were 
deﬁned using ﬂow cytometry size beads of 1–1.4 μm (Spherotech, Lake Forest, IL, USA). For 
the different windows used, the ﬂow cytometer was set on a logarithmic scale. 
Fluorescein isothiocyanate (FITC) anti-human CD47 (BD Pharmingen, San Diego, CA, USA) 
and phycoerythrin (PE) anti-human CD235a (or glycophorin A) (BD Pharmingen) were the 
two antibodies used to tag erythrocyte MPs. Moreover, experiments have been done with 
FITC human annexin V (BD Pharmingen) that tags negative phospholipids present on MPs 
surface. 
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Microparticles counts were determined in the supernatant of a stored EC at 4°C for 38 days, 
after various centrifugation conditions (870 g, 1850 g, 2550 g and 3250 g). Four samples of 
50 ml from the EC were spun down twice for 20 min, and 100 μl of supernatant was then 
mixed with 3 μl of FITC anti-human CD47 or 3 μl PE anti-human CD235a or both for double 
staining. After 20 min of incubation on an orbital shaker in the dark at 4°C, 400 μl of 
phosphate-buffered saline (PBS) was added and ﬂow cytometry analysis was carried out 
within 1 h in a Trucount™ tube (BD Biosciences). Isotypic controls were performed with PE 
immunoglobulin G2b (IgG2b) or FITC IgG1 (both from Diaclone, Besançon, France). MPs 
were also determined in the supernatant of 13 different ECs stored from 2 to 50 days at 4°C 
after two centrifugations at 1850 g for 20 min. Measurements were done in triplicates. The 
ﬂow cytometer settings for counting MPs in supernatants were as follows (detector: voltage): 
FSC: E00, SSC: 360, FL1: 500–600, FL2: 500–600 and FL3: 570. 
Finally, to avoid pre-analytical variability due to centrifugation conditions, MPs counts were 
determined in ECs from seven different blood donors (without centrifugation). For each EC, 
six measurements were performed from day 2 to day 50 of storage at 4°C. Red blood cells 
were carefully mixed with the storage solution, and 5 μl of the RBC suspension was mixed 
with 4 μl of FITC anti-human CD47 for 5 seconds. The mixture was then incubated for 20 
min on orbital shaker in the dark. Lastly, 4 μl of the solution was diluted to 1 ml with 0.9% 
NaCl in a Trucount™ tube, and was directly analysed by ﬂow cytometry. Isotypic controls 
were performed with FITC IgG1 (Diaclone). The ﬂow cytometer settings for counting MPs in 
concentrates were as follows (detector: voltage): FSC: E00, SSC: 300, FL1: 650, FL2: 520 
and FL3: 600. 
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Proteomics 
Proteomic analysis was done on MPs and erythrocyte membranes of the same 42-day stored 
ECs. MPs were obtained after three centrifugations (1850 g twice and 3200 g once, 20 min at 
4°C) and the supernatant containing MPs was collected. Then, three ultracentrifugations at 
120 000 g for 90 min at 4°C were done, each time pellets were suspended in PBS. To obtain 
erythrocyte membranes, RBCs were washed in PBS 10× and spun at 1850 g for 20 min at 4°C 
three times. Collected pellets were then washed in deionized water and after another 
centrifugation at 1850 g for 20 min at 4°C, pellets were collected and prepared for future 
analysis. 
To determine the quantity of sample to load, protein concentration of each sample was 
measured according to the Bradford‟s method [29]. For sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE), 30 μg of proteins was loaded onto a 4–12% 
NuPAGE Novex Bis-Tris polyacrylamide gel (Invitrogen, Carlsbad, CA, USA). The 
migration was carried out at constant voltage (200 V). 
For mass spectrometry (MS) analysis, SDS-PAGE was run as previously described, but 300 
μg of proteins was loaded. Upon electrophoresis completion, the gels were rinsed twice with 
deionized water and stained with colloidal Coomassie blue (National Diagnostics, Atlanta, 
GA, USA) overnight. The gels were destained with deionized water. Bands of interest were 
excised from the gels and transferred into an Eppendorf. In-gel proteolytic cleavage with 
sequencing-grade Trypsin (Promega) was automatically performed in the robotic workstation 
Investigator ProGest (Perkin Elmer Life Sciences) according to the protocol of Shevchenko et 
al. [30]. Digests were evaporated to dryness and resuspended in 3 μl of α- cyano-
hydroxycinnamic acid matrix (5 mg/ml in 60% (v/v) acetonitrile : water), of which 0.7 μl was 
deposited in duplicate on a target plate. Matrix-assisted laser desorption/ionization MS 
(MALDI-MS)/MS analysis was performed on a 4700 Proteomics Analyser (Applied 
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Biosystems, Framingham, MA, USA). After MALDI – Time of Flight (TOF)/MS analysis, 
internal calibration on trypsin autolysis peaks and subtraction of matrix peaks, the 10 most 
intense ion signals were selected for MS/MS analysis. Non-interpreted peptide tandem mass 
spectra were used for direct interrogation of the Uniprot (Swissprot + TrEMBL) database 
using Mascot 2.0 (http://www.matrixscience.com). The mass tolerance for database searches 
was 50 p.p.m. MASCOT was set up to only report peptide matches with a score above 14. 
With the parameters used, the threshold for statistical signiﬁcance (P < 0·05) corresponded to 
a total (protein) MASCOT score of 33. Proteins scores above 80 were automatically 
considered valid, while all protein identiﬁcations with a total MASCOT score between 33 and 
80 were manually validated. Validation included examination of the peptide root mean square 
mass error and of individual peptide matches. Peptide matches were validated only if at least 
an ion series of four consecutive y ions were matched, in addition to ions belonging to other 
series. Generally, only proteins matched by at least two peptides were accepted. 
 
Western blotting 
From 20 to 50 μg of proteins from the samples described before (MPs and erythrocyte 
membranes) were loaded onto a 4–12% NuPAGE Novex Bis-Tris polyacrylamide gel 
(Invitrogen). After migration, carried out at constant voltage (200 V), proteins were 
transferred to polyvinylidene ﬂuoride membranes using a Novex blot module (Invitrogen) for 
1 h 45 min at ﬁxed voltage (30 V), according to the manufacturer‟s instruction. After transfer, 
blotted membranes were soaked overnight in blocking solution with PBS, 0·1% Tween-20 (v/ 
v), 5% milk and 1% BSA (w/v). Four Western blots were done, each one with a different 
antibody, namely, anti-human CD235a (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti-human actin (Sigma, Saint Louis, MO, USA), anti-human stomatin (Proteintech Group, 
Chicago, IL, IL) and anti-human CD47 (from Santa Cruz or from AbCam, Cambridge, UK). 
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All antibodies were used at a dilution of 1 : 500. The goat anti-rabbit and goat anti-mouse 
horseradish peroxidase-conjugated secondary antibodies (Dako, Baar, Switzerland) were both 
used at a dilution of 1 : 10 000. Subsequent visualization was performed using enhanced 
chemiluminescence (GE Healthcare, Uppsala, Sweden). The signal was ﬁnally captured using 
X-ray ﬁlm. 
 
Expression of Rhesus antigens 
Flow cytometry was used to determine the presence of Rh antigens on MPs generated during 
storage. MPs were ﬁrst isolated from the supernatant of an EC after two centrifugations at 
1850 g at 4°C for 20 min. The supernatant was then spun down at 18 000 g for 5 min to pellet 
MPs. Pellet was dissolved in 100 μl of PBS. One μl of the primary antibody (anti-D, anti-C, 
anti-c, anti-E and anti-e, respectively) was later added and mixed on orbital shaker for 90 min. 
IgM anti-D were obtained from Orthobiotech (Bridgewater, NJ, USA), whereas IgM anti-C, 
IgM anti-c, IgM anti-E and IgM anti-e were obtained from Biotest (Dreichen, Germany). One 
μl of the secondary antibody was then added, and after 1 h on orbital shaker in the dark, 400 
μl of PBS was added, and samples were analysed by ﬂow cytometry within an hour. 
Secondary antibody directed against primary IgM was FITC anti-human IgF(ab) from 
Chemicon (Melbourn, Australia). To demonstrate the presence of various Rh antigens on 
MPs, blood samples expressing different Rh phenotypes, such as DCCee, DccEE or dccee, 
were selected. The antithetical phenotype was used with each antibody as a negative control. 
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Results  
 
Microparticle counts 
Using ﬂow cytometry, MPs clearly were distinguished from RBCs by their size as well as by 
the negatively charged phospholipids on their outer membrane detected by annexin V. Indeed, 
the great majority of MPs were annexin V-positive, while merely a few percentage of 
erythrocytes were positive. MPs were also identiﬁed using either anti-CD47, anti-CD235a or 
both antibodies, without any differences in their numbers according to the choice of the 
antibody (Figs 1 and 2). In both methods used, an increase in the number of MPs during 
storage of ECs was observed (Figs 2 and 3). The number of MPs was clearly related to 
centrifugation conditions (Fig. 2). In the measurements performed directly in the concentrate, 
the number of MPs increases about 20-fold after 50 days of storage at 4°C and considerably 
varies among different samples; it starts from 3370 + 1180/μl after 6 days, up to 64 850 + 37 
800/μl after 50 days of storage (Fig. 3). The intra-assay coefﬁcient of variation was evaluated. 
With both methods, the coefﬁcient was less than 15%, even after 50 days of storage (data not 
shown). Nonetheless, and without evident explanation, we observed a huge individual 
variation of the MPs counted among different donors. 
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Fig. 1 Flow cytometry analysis of 
microparticles from a supernatant after 
centrifugation of erythrocyte concentrate. 
(a) Events that were sorted according to 
their size and shape. Two different regions 
were determined; microparticles and beads. 
A precise number of beads were used to 
determine the number of microparticles in 
each sample. Histograms represent events 
from the microparticle region (b–e) of (a) 
according to their ﬂuorescence (due to an 
FITC- or PE-labelled antibody). M1 
represents non-stained events whereas M2 
shows stained event. (b) Microparticles 
stained with annexin V; (c) microparticles 
stained with anti-CD47 FITC; and (d) 
microparticles stained with anti-CD235a. 
FITC, ﬂuorescein isothiocyanate; PE, 
phycoerythrin. In (e) and (f), microparticles 
were derived from an erythrocyte 
concentrate from a donor typing dccee. In 
this example, microparticles were negative 
for anti-C antibody (e), while they were 
positive for anti-c antibody (f). 
 
 
Fig. 2 Count of microparticles in 
supernatant of erythrocyte 
concentrates (ECs). The number of 
microparticles measured decreased 
with increasing centrifugation 
speed (test on one EC stored for 
38 days). Note that the numbers 
measured were identical with the 
two antibodies used in this study 
(anti-human CD235a or CD47). 
The inset shows an increase in the 
number of microparticles in 
supernatant of ECs during storage 
(after centrifugation at 1850 g, 
here anti-human CD235a was used). 
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Fig. 3 Count of microparticles 
directly in erythrocyte concentrates 
during storage (without 
centrifugation). Data are expressed 
as the mean ± SD experiment (n = 7). 
At day 5, 3371 ± 1188 
microparticles/μl were counted, 
whereas at day 50, their numbers 
were 64 858 ± 37 846 
microparticles/μl. Anti-human CD47 
was used to stain microparticles 
 
 
 
Proteomics 
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis showed a number of large as 
well as discrete bands obtained after electrophoresis of RBC membranes (Fig. 4, lane A) and 
MPs (Fig. 4, lane B). A major difference was observed in the 25–35 kDa region; thus, in order 
to perform protein identiﬁcation, bands of interest stained with Coomassie blue were excised 
and proteins were identiﬁed by MS. Table 1 lists the proteins identiﬁed in the three excised 
bands of lane A (erythrocyte membranes) and lane B (MPs). Not surprisingly, abundant 
proteins such as carbonic anhydrases or peroxiredoxins were identiﬁed both in RBC 
membranes and MPs with good sequence coverage. A set of 14-3-3 proteins was also 
identiﬁed in both samples: 14-3-3 proteins are abundant and ubiquitous proteins [31] that act 
as regulators of a number of processes, such as modulation of protein kinase activities, signal 
transduction [32]. Remarkably, 14-3-3ζ has been shown to be implicated in GPIb-IX-V 
translocation to the cytoskeleton during platelet activation [33]. It was thus not surprising to 
ﬁnd 14-3-3 proteins in RBC ghosts. The gel band that appeared to be quantitatively the most 
different between lanes A and B was identiﬁed as stomatin, identiﬁed in MPs with a score of 
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1131, a sequence coverage of 76·4% from 46 peptides, whereas it was identiﬁed in RBC 
membranes with a score of 156, a sequence coverage of 14·9% from four peptides, indicating 
that stomatin was largely enriched in MPs compared to erythrocyte membranes. 
 
Interestingly, some of the identiﬁed proteins did not have molecular weights that 
corresponded to their respective position on the gel. For example, haemoglobin subunits α and 
β, which have a molecular weight of about 15–16 kDa, were observed in the region 
corresponding to 25–35 kDa on the gel. However, it has been documented that denatured and 
cross-linked haemoglobin strongly binds to the cytoskeleton during RBC storage in blood 
banking conditions [34]. It is thus highly probable that the haemoglobin subunits identiﬁed 
were present as homogeneous or heterogeneous dimers. Additionally, Band 3 (a major 
membrane protein) as well as Rhesus protein were identiﬁed in MPs only, from three and two 
sequenced peptides, respectively. For Band 3, the identiﬁed peptides correspond to the 
cytoplamic domain of the protein (spanning the region 117–180), which means that the Band 
3 fragment that appears on the gel in the 25–35 kDa region belongs to the cytoplasmic domain 
of the protein. The Rhesus protein was identiﬁed from two peptides covering the 17 last 
amino acids on the C terminus of the protein sequence. Of interest, Mascott allowed the 
identiﬁcation of Rh peptides (Table 1; lane B of Fig. 4). However, it was not possible to 
discriminate between RhD and Rh(CE) proteins, a well-known problem in proteomics [35]. 
Nevertheless, the presence of various Rh antigens at the surface of MPs was conﬁrmed by 
ﬂow cytometry (see below). 
 
 66 
 
Fig. 4 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) of 
erythrocyte membranes and microparticles, both were from a 42-day stored erythrocyte 
concentrate. The gel was stained with Coomassie blue (for better compatibility with mass 
spectrometry). Inset shows enlargement of Coomassie blue-stained gel used for the 
preparation of the bands submitted to mass spectrometry analysis. Western blot analysis 
points out the variation of protein expression. Thus, by comparing erythrocyte membranes 
and microparticles, a clear reduction of actin and an accumulation of stomatin were observed 
on microparticles. The staining of CD235a (glycophorin A) was similar in both gels. 
 
Western blots 
Western blotting conﬁrmed the presence of CD235a, actin and stomatin on RBC membranes 
as well as on MPs, with a clear reduction of actin and an accumulation of stomatin on MPs 
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(Fig. 4). However, using this technique and the antibodies available, neither CD47 nor Rh-
proteins could be detected after SDP-PAGE. With blot techniques, no quantitative difference 
was observed between MPs samples from ECs stored for 5 or 42 days. 
 
Rhesus systems 
The presence of blood group antigens of Rhesus system on MPs surface was investigated by 
ﬂow cytometry using speciﬁc antibodies. In each assay, positive and negative samples were 
selected for the corresponding antigen (Fig. 1e,f ). By this approach, the presence of C, c, D, 
E or e antigens was observed on MPs when they were present on the RBCs from which they 
derived. However, it was not possible to exclude that a population of MPs was Rh negative.  
 
Table 1 Proteins identiﬁed in the region 25–35 kDa of RBC membranes (lane A of Fig. 4) 
and microparticles (lane B of Fig. 4). Reported are the sequence coverage (%) and the number 
of sequenced peptides 
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Discussion 
 
There is no standardized method to count MPs. Several approaches have been proposed in the 
literature, the majority dealing with platelet MPs from whole blood or platelet concentrates. 
Centrifugation speeds, for MPs characterization, varied from 200 g to 13 000 g [36]. In our 
hands, complete elimination of RBCs from supernatant at low centrifugation was obtained 
after two centrifugation at 1850 g for 20 min. Annexin V is frequently used to detect 
phosphatidylserine, a negatively charged phospholipid known to be present on the outer 
leaﬂet of apoptotic cells as well as on MPs of various origins [18]. In this study, MPs were 
counted using ﬂow cytometry with different antibodies, notably anti-CD235a and anti-CD47. 
These antibodies were chosen because both are reactive towards RBC membrane molecules 
known to be present on MPs [14,29]. 
Counting MPs directly within the homogenized ECs appeared as the simplest approach, 
avoiding handling, centrifugation and washing. The drawbacks were due to the presence of a 
great number of RBCs, the need of quite large amount of antibodies and an intra-sample 
variability in the number of MPs counted. In addition, samples cannot be stored, contrasting 
with supernatants containing MPs, which can be kept at 4°C or even be frozen before being 
evaluated by ﬂow cytometry. Disadvantages of working with supernatants were related to the 
handling procedures and, more importantly, to the inﬂuence of centrifugation conditions. 
After centrifugation, residual RBCs were eliminated. However, a number of MPs appeared to 
be pelleted together with RBCs (Fig. 2). In any case, an increase in the number of MPs in ECs 
during storage was observed, even if the number of MPs counted differs according to the 
method. From our results, it is really clear that the number of MPs counted in EC was 
dependent on the centrifugation protocols. 
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Whereas it cannot be excluded that MPs from platelets, white blood cells or endothelial cells 
be present in the starting EC, this increase in total of MPs count can be attributed only to the 
shedding of MPs from RBCs present in the concentrate. Noteworthy, the increase varied quite 
importantly from donor to donor. The reason of such a variation is unknown, but factors like 
ABO blood group, age, fasting or sex of blood donor may have a role and should be 
investigated. Finally, the most important parameter associated with the number of MPs in ECs 
was the duration of storage at 4°C. A set of experiment with three ECs satisfying quality 
criteria for transfusion (normal ALAT level) was done and gave very similar, if not identical 
MPs count when compared to ECs with elevated ALAT level (data not shown). 
Microparticle tend to aggregate at high concentration, either related to the methods used for 
their isolation or to their „intrinsic‟ adhesion properties, which have been already evidenced 
with platelet-derived MPs [16]. We observed heaps of erythrocyte MPs by electron 
microscopy (data not shown), thus erythrocyte MPs may also have adhesion properties. This 
observation is important for the quantitative results, because MPs counts are evaluated 
according to their sizes using ﬂow cytometry. Thus, in samples with high concentrations of 
MPs, their number are probably underestimated due to the fact that MPs tend to form more 
heaps and ﬂow cytometry does not distinguish between big MPs or aggregated MPs, even if 
the technique is the method of choice to study MPs [36]. So, the counting approach of MPs 
presented in this study (as well as in other published studies) should be considered as 
semiquantitative. 
According to our proteomic and Western blot studies, MPs from stored RBCs appeared to be 
enriched with stomatin. Remarkably, the enrichment in stomatin, depletion in actin and 
stability of glycophorin A (as compared to erythrocyte membranes) were the same at day 7 
and day 40. In this respect, MPs generated after a few days of storage or at the end of storage 
appear equivalent. Those results are well in line with previous reports [37,38]. Stomatin is a 
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membrane protein involved in regulation of monovalent cation transport through lipid 
membranes [39]. Interestingly, stomatin (which has a structure similar to caveolin) is a major 
lipid-raft component of erythrocytes [40]. Precise reasons of stomatin enrichment in MPs are 
not well known and are still subject of investigation, but may have a role in membrane 
microdo- mains modulation leading to membrane budding and MPs release [38]. The cell 
membrane plays a key role in the formation of MPs. Indeed, following a stimulus, increase in 
intracellular Ca++ occurs and activates proteases that cleave cytoskeleton proteins (actin and 
spectrin). Membrane is thus less rigid and can bud until formation of MPs. Furthermore, the 
asymmetry between the neutral phospholipids on the outer membrane and the negatively 
charged phospholipids on the inner membrane held by translocases is broken [37]. 
Consequently, phosphatidylserine, a negatively charged phospholipid, is also located on the 
outer side of MP membrane. Using annexin V, ﬂow cytometry conﬁrmed that 
phosphatidylserine was present on MPs derived from erythrocytes but essentially lacked from 
fresh RBCs and was externalized in only a small fraction of old RBCs. Finally, as shown by 
Western blots, actin was not a dominant protein of MPs when compared to RBC membranes. 
The precise reasons for the huge increase in MP counts during storage of EC observed in this 
study are unknown. Although controversial, it has been speculated that MPs could be a means 
for erythrocytes to prevent a premature removal from circulation when they are still 
functional or when lesions are reversible [41]. According to this hypothesis, MPs would allow 
erythrocytes to clear away non-functional molecules that would trigger an apoptosis-like 
pathway, or to get rid of autologous IgG binding senescent erythrocytes for removal by spleen 
macrophages [8,10,42]. Indeed, Willekens et al. have recently shown that MPs contain 
erythrocyte removal proteins such as bound IgG and altered Band 3, and thus concluded that 
microvesiculation serves as a removal pathway for damaged proteins [42]. Complementarily, 
a detailed proteomic investigation of RBCs and MPs generated during storage led Bosman et 
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al. to hypothesize that there are two possible mechanisms at work in MPs generation: ﬁrst, 
immunoglobulins could bind to senescent surface proteins, thereby triggering 
microvesiculation. Alternatively, oxidatively damaged proteins could bind to or disrupt 
normal interactions within the cytoskeleton, thereby altering the tight balance between the 
cytoskeleton pressure and the membrane bending stress [10]. These two passive mechanisms 
could well be only one part of the picture, because activation of protein kinases has been 
demonstrated to trigger phosphatidylserine exposure in erythrocytes [43], as well as tight 
concomitant regulation of microvesiculation and Band 3 phosphorylation/ dephosphorylation 
[44]. Lastly, lysophosphatidic acid, an important lipid mediator, has been shown to be able to 
trigger phosphatidylserine exposure and microvesiculation in erythrocytes [45]. These studies 
show that MP generation can be triggered by various processes, including senescence or 
protein alteration, external or internal exposure to lipid mediators, and that phosphorylation 
plays a role in microvesiculation control. 
In this study, we also showed evidence that Rhesus blood group antigens are located on 
erythrocyte MPs. The presence of these proteins was evidenced by determination of Rh 
peptides by MS and by ﬂow cytometry, indicating that the antigenic parts of the Rh proteins 
are located outside MPs membranes. The presence of the Rh complex is also reinforced by the 
expression of CD47 (shown by ﬂow cytometry), which is a member of the complex within the 
RBC membrane. Those blood group antigens present on MPs are likely immunogenic, and 
thus may play a potential role in RBC alloimmunization after transfusion. 
As recently shown by Koch et al., there is a link between duration of RBC storage and 
complications after cardiac surgery [28]. According to the result of this research, trans- fusion 
of erythrocytes that have been stored for more than 14 days in patients undergoing cardiac 
surgery signiﬁcantly increases the risk of postoperative complications and reduces survival 
time. Reasons for such complications remain unclear; however, storage lesions may be a 
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possible mechanism. Physicochemical changes occurring during storage of ECs are indeed 
known to affect RBCs function and viability. Our results conﬁrm that important changes 
occur during storage of RBCs and that storage techniques allowing a better con- servation of 
the integrity of the membrane should be thus developed in the future. 
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Abstract  
 
Microparticles are phospholipid vesicles shed mostly in biological fluids, such as blood or 
urine, by various types of cells, such as red blood cells (RBCs), platelets, lymphocytes, 
endothelial cells. These microparticles contain a subset of the proteome of their parent cell, 
and their ready availability in biological fluid has raised strong interest in their study, as they 
might be markers of cell damage. However, their small size as well as their particular 
physico-chemical properties make them hard to detect, size, count and study by proteome 
analysis. In this review, we report the pre-analytical and methodological caveats that we have 
faced in our own research about red blood cell microparticles in the context of transfusion 
science, as well as examples from the literature on the proteomics of various kinds of 
microparticles. 
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Introduction  
 
By its importance for living organisms, blood is often called “fluid of life”. Transfusion is 
indeed vital and indicated in numerous clinical situations such as severe haemorrhage, 
anaemia or hypovolemia, in which case red blood cell (RBC) concentrates are administered to 
sustain the oxygenation of tissues, haemostasis imbalance or disorders, in which case platelet 
concentrates are administered, or deficiency of coagulation factors (transfusion of fresh frozen 
plasma). Since the beginning of transfusion, numerous efforts have been made to secure blood 
products and gain knowledge about their molecular structures. With millions of blood product 
transfused worldwide every year, each incremental piece of progress has a potential broad 
effect on a great number of lives. Nevertheless, there is still a risk of side effects associated to 
transfusion such as fever, inflammation, and iron overload or autoantibody formation [1,2]. 
 Erythrocyte concentrates (ECs), platelet concentrates (PCs) and fresh frozen plasma (FFP) 
are the three main labile blood products and have to be stored according to their particular 
components. Those components are subjected to modifications or degradations during 
storage, a process known as the “storage lesion” [3]. RBC ageing in blood banking conditions 
differs from physiological in vivo ageing. Indeed, conditions to which RBCs are exposed 
during storage, such as temperature and nature of the medium, are dramatically different from 
physiological conditions. Several preservative solutions such as citrate–phosphate–dextrose–
adenine (CPDA), saline–adenine–glucose–mannitol (SAGM) or phosphate–adenine–glucose–
guanosine–saline–mannitol (PAGGSM) are available in routine [4]. These additive solutions 
allow to store red blood cell concentrates from 35 days up to 49 days in accordance with the 
European transfusion standards [5], requiring that at least 75% of erythrocytes must survive in 
vivo 24-h after transfusion (see Table 1). During storage many physiological and biochemical 
alterations occur in the supernatant of ECs including an increase in the concentration of lipids, 
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MPs, free haemoglobin and a pH reduction. Red blood cells also undergo several changes 
such as loss of potassium, adenosine triphosphate or 2,3-diphosphoglycerate. Their 
membranes become more rigid, there is a disruption of phospholipid asymmetry, lipid raft 
rearrangement, loss of fragments or even release of MPs [6]. The effects of storage lesions, 
including the shedding of MPs, on transfusion efficiency and potential side effects are not 
clearly understood. Among other approaches, proteomics allows the investigation of 
important issues in blood research [7] and transfusion science [8] in order to gain better 
knowledge of the blood products delivered to patients as well as gain insight into the 
mechanisms at work in transfusion side effects.  
This review focuses on methodological and analytical challenges in the proteomic analysis of 
red blood cell-derived microparticles. However, examples from other microparticle types 
(platelet, endothelial,. . .) are discussed as well to highlight some analytical or methodological 
aspects. Moreover, whereas flow cytometry is a central tool for the analysis of microparticles, 
it is beyond the scope of this review to discuss the various techniques used to analyze 
microparticles by flow cytometry. Excellent reviews have been published [9], and we discuss 
here only challenges and recent development in flow cytometry. 
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What are microparticles ?  
 
MPs are plasma membrane vesicles shed in blood flow by various types of cells such as 
platelets, red and white blood cells, or endothelial cells. Those MPs, also known as 
microvesicles [10] or in some cases as ectosomes [11] have a size of less than 1µm [12] and 
contain a subset of proteins derived from their original cells as well as surface receptors 
allowing the identification their origin. Most studies generally agree that MPs are 
heterogeneous and vary in size, concentration, phospholipid composition, surface antigens 
and protein content. Release of MPs is thought to be a highly controlled process prompted by 
various stimuli such as shear stress, complement attack, pro-apoptotic stimulation or damage 
[13]. Although still subject to discussion, a model of vesiculation has been established. This 
model brings in translocases, lipid rafts, various protein modifications and irreversible 
membrane rearrangements. [14]. Recently, an association between erythrocytes aging 
processes and MPs formation has been proposed as a part of an apoptosis-like form in 
erythrocytes [15]. This “aging” process of red blood cells has also been observed during 
storage in blood bank condition [16].  
MPs have long been considered as cell fragments or “dust” without any biological role. 
Although their functions are still largely unknown, there are more and more evidences that 
MPs are involved in a broad spectrum of biological activities [14] such as haemostasis [17], 
thrombosis [12], inflammation [17], transfer of surface proteins [18] or even angiogenesis 
[19]. 
In the case of haemostasis, MPs provide an additional negative phospholipid surface for the 
assembly of the tenase enzymatic complex involved in the coagulation cascade [20]. 
Moreover, a study demonstrated that platelets MPs have from 50 up to 100- times more 
procoagulant activity than platelets [21]. Nonetheless, not only platelet MPs are involved in 
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this process, indeed, erythrocyte MPs and other MPs have a procoagulant activity as well 
[22]. In addition, a recent paper by Furie and Furie [20] mentions a “microparticles 
accumulation pathway” as a part of the coagulation process. Briefly, according to this model, 
there are constitutive MPs at low concentration expressing inactive tissue factor (TF). These 
MPs are then captured in a developing thrombus and their accumulation in the injury site 
leads to activation of MPs TF and helps to amplify coagulation.  
Another impelling example is the implication of MPs in erythrocyte ageing process [23]. 
Indeed, during their 120 days of lifespan, red blood cells lose between 15% and 20% of their 
volume and haemoglobin concentration increase by 14% [24]. Thus, microvesiculation would 
be amean for red blood cells to eliminate denatured haemoglobin which could be toxic [25], 
and besides, microparticles release would also be a mean for red blood cells to get rid of 
specific membrane proteins which could prevent or induce their removal from blood flow 
according to the situation. In a protective role, MPsmay help to clear away the C5–9 
complement attack complex, band 3 neoantigen, IgG or other harmful agent from the 
membrane when the red blood cell is still viable [13,25–28], and thus prevent early removal 
from blood flow. In contrast, MPs could promote removal of erythrocytes: CD47 is an 
integral membrane protein present on erythrocytes surface, acting as a marker for self [23]. 
Thanks to CD47, normal red blood cells are recognized as self by the macrophages (through 
their signal regulatory protein alpha) and phagocytosis is inhibited. Senescent or damaged red 
blood cells whose CD47 expression is reduced by shedding of MPs enriched in CD47 would 
be no longer recognized as self and thus be eliminated by macrophages.  
Although the presence of MPs in blood is common in healthy individual, an increase in the 
concentration of MPs in plasma has been demonstrated under various pathological conditions 
such as thrombocytopenic disorder [29], cardio vascular disease [30], diabetes [31] or sepsis 
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[32]. It is also important to refer that a fewpathologies such as Scott syndrome [33] are linked 
to decrease in MPs concentration in plasma. 
In ECs and platelet concentrates, an increase in the number of MPs during storage has been 
evidenced [34,35]. Although MPs have been detected in FFP too, in contrast to ECs and PCs 
containing cells, there is no increase in MPs during storage. It has been proposed that MPs are 
implicated in different vascular pathologies. For example, a recent paper by Lawrie et al. [36] 
has demonstrated the effect of MPpresence on clotting time of FFP. Thus, as MPs affect the 
clotting time, they could alter the quality of the blood product. Whereas the overall impact of 
MP presence on the blood product value is still largely unknown, there is little chance that 
their presence be totally innocuous. 
Table 1 The development of RBC storage solutions. ACD, acid citrate dextrose; AS-3, additive solution 3; CPD, 
citrate phosphate dextrose; CP2D, high dextrose CPD; CPDA-1, CPD plus adenine; CPDA-2, CPD with adenine 
and extra dextrose; ½ CPD, half volume CPD; PAGGSM, phosphate, adenine, glucose, guanosine, saline and 
mannitol; RAS-2, research additive solution 2; SAG, saline adenine glucose; SAGM, SAG plus mannitol. 
Adapted from Ref. [4]. 
 Typical recovery Haemolysis Vesicles 
Three-week storage 
ACD 75%[63] 0.1%[63]  
CPD 79%[63] 0.1%[63]  
Five-week storage 
CPDA-1 72%[64] 0.5%[64] 70%[65] 
CPD/SAG 83%[66] 0.6%[66]  
Six-week storage 
CPDA-2 80%[67]   
CPD/SAGM 78-84%[66] 0.4%[66] 25%[68] 
CP 2D/AS-3 78-84%[66] 1.0%[66]  
Seven-week storage 
CPD/PAGGS-M 74%[69] 0.5%[69]  
1/2CPD/RAS2 78%[70] 0.5%[70]  
Eight-week storage 
CPD/EAS-81 85%[68] 0.4%[68] 10%[68] 
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Methods of microparticle analysis 
 
The increasing interest in MPs lies in the fact that as they circulate in blood flow, they could 
constitute hallmarks of cellular activation or damage. Therefore new efficient methods have to 
be developed with the aim to obtain qualitative or/and quantitative data on MPs. It is 
important to add that there is no standardized method for MPs analysis, making any 
comparison difficult between different studies. In order to analyze MPs, several approaches 
are available in the literature such as electron microscopy, ELISA, proteomic methods and 
flow cytometry [9,37]. 
 
Isolation of MPs from biological medium 
Prior to analyze MPs, isolation or concentration of MPs from samples (whole blood, platelet 
or red blood cells concentrate, fresh frozen plasma) could be needed according to the 
experiment. Indeed, in most studies, classical differential centrifugation (see Table 2) is 
principally employed. Notice that the references in Table 2 deal with platelet MPs, 
nevertheless it is a good illustration of the plentiful isolation methods available. For 
centrifugation, there are two main steps for MP isolation. First, low speed centrifugation 
(from 200 to 13,000×g) removes intact cells, which leaves a MP-rich supernatant that can be 
directly analyzed. Alternatively, a second high-speed centrifugation (18,000–100,000×g) can 
be used to pellet microparticles from the supernatant. Worth noticing is that most studies deal 
with platelet MPs, and that centrifugation conditions have to be adapted from one cell type to 
the other. Fig. 1 shows the optimisation of the centrifugation conditions to remove RBCs from 
ECs while keeping the MPs in the supernatant. In our experience, the best centrifugation 
conditions were determined to be two centrifugations at 1850×g, 4◦C, 20 min, to remove all 
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RBCs from the supernatant. In these conditions, there is a 15-fold loss of microparticles 
compared to untreated EC, but there are no detectable RBCs in the supernatant. In cases when 
concentrated microparticles are necessary (for example for proteomic studies), an additional 
ultracentrifugation is usually performed to pellet MPs from the supernatant; this is usually 
accomplished by centrifuging the MP-rich supernatant at 100,000×g to obtain a MP-free 
supernatant. The main drawback of this approach is that the MP pellet might also contain a lot 
of contaminants. It is our experience that the RBC supernatant after low speed centrifugation 
contains mainly MPs that can be detected and counted by flow cytometry with cell-specific 
markers (such as antibodies against CD47 or CD235a) or markers of phosphatidylserine 
externalization such as Annexin V, with very little background noise. On the contrary, when 
microvesiculation is induced in vitro by challenging RBCs with calcium ionophore or calcium 
alone, there is a huge increase in the number of small fragments of the same size as MPs (at 
least as can be estimated from flow cytometry, see below), but that are negative to any 
labeling with anti-CD47, anti-CD325a and Annexin V. When pelleting the MPs by 
ultracentrifugation, there is no doubt that a large part of these fragments are pelleted as well 
and may obscure the biologically relevant information about MPs. 
 
Fig. 1  
Count of microparticles in 
supernatant of ECs. The 
number of microparticles 
measured decreased with 
increasing centrifugation speed 
(test on one ECs stored for 38 
days). Note that the numbers 
measured were identical with 
the two antibodies used in this 
study (anti-human CD235a or 
CD47). Adapted from [34]. 
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Table 2 Classical methods for MP isolation reported in the literature. Adapted from Ref. [37]. 
 
 
MP counting 
As mentioned above, an increase in the number of MPs in blood is linked to various 
pathologies, hence the idea of using MPs as biomarker and thus the need to develop method 
allowing to quantify MPs. Flow cytometry is often considered as the method of choice to 
analyze MPs, indeed it allows analyzing thousands of MPs in one sample of whole blood or in 
a fraction with determination of many different markers at the same time. Additionally, flow 
cytometry enables not only qualitative but also semi-quantitative analysis. However, as MPs 
have a size smaller than 1µm, this requires working at the inferior limits of the instrument, 
which have for consequences a loss of precision and/or accuracy. In addition, flow cytometry 
is not able to distinguish MPs, small cell debris and aggregates of MPs. This observation is 
confirmed by electron microscopy of erythrocyte MPs from EC: their size is around 0.15µm 
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and they tend to form clumps consisting of 10–15 MPs with an aggregate size of 1µm (see 
Fig. 2). Note that whereas in Fig. 2, MPs are issued from stored erythrocytes, however similar 
observations have been made in sample from treated red blood cells [38]. 
 
In our hands, flow cytometry analysis was performed with TruCount tubes (with a precise 
number of fluorescent beads to determine the number of MPs in a sample) and fluorescent 
cell-specific antibodies (either anti-CD47 or anti-CD235a) or phosphatidylserine-specific 
Annexin V. It was found that during storage of ECs in blood bank conditions, the number of 
MPs increased from around 3300±1200 MPs/µl at day 5 of storage and it increases up to 
64,000±37,000 MPs/µl after 50 days of storage (the storage limit being of 42 or 49 days 
depending on the additive solution used, see Table 1).  
Interestingly, a wide variability between the different concentrates was observed (see Fig. 3). 
The variation is likely due to the physico-chemical changes that occur in blood units during 
storage. Those changes affecting erythrocyte‟s viability reinforce and accelerate haemolysis 
and the associated release of MPs. Changes take place at different storage time, more or less 
rapidly according to the blood donor; indeed this might be caused by intrinsic factor such as 
sex, age, health, genotype, or diet, due to the fact that each sample was identically processed. 
Fig. 2  
Pictures of erythrocyte microparticles taken by 
scanning electron microscopy. (A) Magnification of 
4000×,MPs surrounding an erythrocyte. (B) 
Magnification of 37,000×, heap of MPs. 
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Fig. 3 
Count of microparticles directly 
in erythrocyte concentrates 
during storage (without 
centrifugation). Data are 
expressed as the mean±SD 
experiment (N= 7).  
At day 5, 3371±1188 
microparticles/µl were counted, 
whereas at day 50, their 
concentration was 
64‟858±37‟846 microparticles/µl. 
Anti-human CD47 was used to 
label MPs [34]. 
 
 
 
Pre-analytical factors 
It has been observed that factors such as temperature, shaking, or the dilution buffer influence 
the number of MPs counted; it is not totally clear from the literature and our experience if 
these factors affect the MPs counts by favouring MP in vitro aggregation, for example, or if 
they indeed induce artifactual microvesiculation of RBCs.  
The impact of sample manipulation out of the cold room was tested with a fresh EC split in 2 
similar blood bags. One was simply stored at 4 ◦C for 40 days while the other one was put out 
of the cold room for 1 h twice a week (i.e. 10 times during 40 days). MPs were then counted 
after 40 days according to the methods described by Rubin et al. [34]. The experiment was 
performed on two different concentrates and in both, much more MPs were observed in bags 
that underwent 10 cycles of 4 ◦C–room temperature (see Fig. 4). Another experiment to test 
the impact of working temperature was done with two different ECs, one stored for 15 days 
and the other one for 38 days in standard blood banking conditions. Few millilitres of each EC 
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were incubated for 1 h at three different temperatures (4, 24 and 37 ◦C, respectively). Samples 
were then centrifuged and MPs were counted in the supernatant by flow cytometry. Fig. 5 
shows the variation in MP concentration for the two different samples handled at 4, 24 and 37 
◦C. Not surprisingly, the EC stored for 38 days contains more MPs than the one stored for 15 
days, but both samples show that increasing handling temperature induces a higher MP 
concentration. 
Moreover, the solution used to dilute MP samples just before flow cytometry analysis also has 
an influence on MP counts. Here, three different ECs, stored for 2, 8 and 43 days in standard 
blood banking conditions, were diluted in different solutions: PBS, NaCl 0.9% and FACS 
Flow (FF) solution (BD Biosciences, Franklin Lakes, NJ). Flow cytometry analysis was 
performed as quickly as possible after the dilution of the sample. While the variation in the 
number of MPs was relatively small in concentrates stored for 1 and 8 days according to the 
buffer, a large increase of MPs was observed in the samples diluted in PBS compared to other 
buffers, as shown in Fig. 6. 
An experiment to test if freezing/thawing sample of MPs free of cells affects MP counts has 
been conducted. Indeed, comparisons between MPs count in fresh supernatant and in 
supernatant frozen once have been done on ECs stored from 9 to 45 days (both supernatant 
were issued after two centrifugations of erythrocytes concentrates). Briefly, MPs were labeled 
and then counted by flow cytometry according to the protocol designed by Rubin et al. [34]. 
Notice that freezing sample could only be done after centrifugation, on cell-free samples. The 
difference between fresh and frozen supernatants does not exceed the standard variation 
coefficient of our standard experiment, which usually is from 3% to 13%. To give an 
example, in a 16 days stored sample, the difference between thawed and non-frozen sample 
was around 3%. So, MP counting, sample freezing did not affect the number of MPs detected.  
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Finally, the impact of shaking on MP count was checked: few millilitres of two different 
erythrocyte concentrates (the first one stored for 8 days and the other one stored for 42 days) 
were shaken using a Vortex mixer for different times (5, 10 and 20 s). Flow cytometry 
analysis was finally performed in the concentrate with TruCount tubes to count MPs 
beforehand stained with anti-CD47. Fig. 7 shows the increase in microparticle concentration 
after various vortexing times.  
 
Fig. 4.  
Effect of cold room/RT cycles on 
MP counts. White bars represent 
samples continuously kept at 4 ◦C, 
black bars represent samples 
exposed 10 times to room 
temperature during storage. 
 
 
 
 
 
Fig. 5.  
Effect of handling temperature on 
MP concentration (white bars 
represents samples handled at 4 ◦C, 
grey bars at 24 ◦C, and black bars 
at 37 ◦C). 
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Fig. 6.  
Effect of the dilution solution used for 
flow cytometry analysis on the MP 
count after 2, 8 or 43 days of storage 
in standard blood banking conditions. 
White bars correspond to PBS, grey 
bars to NaCl 0.9%, black bars to 
FACS Flow. 
 
Fig. 7.  
Effect of vortexing on theMPcount. 
White bars correspond to a 5 s 
vortexing, grey bars to a 10 s 
vortexing, and  dark bars to a 10 s 
vortexing. 
 
 
These four examples illustrate the impact of sample handling, dilution, and manipulation on 
the measured microparticle concentration. Whereas no clear rationale exists for the observed 
effects, some guidelines can be drawn from these experiments: 
(1) The measured MP concentration does not depend on the detection system used (be it cell-
specific antibodies or phosphatidylserine-specific Annexin V), as shown in Fig. 3.  
(2) All other factors might have an influence on the measured MP concentration, and best 
efforts should be made to standardize sample handling and preparation as much as possible; 
this is especially true for the temperature to which sample are exposed, the solution used to 
dilute the sample before flow cytometry analysis, and the way solutions are mixed. 
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Microparticle counting and sizing 
To return to MPs count, a solid-phase method was developed by Nomura and co-workers [39] 
allowing indirect quantification of MPs. Briefly, Annexin V coated plates are used to capture 
phosphatidylserine-exposing microparticles. After washing, the (indirect) procoagulant 
activity of the bounded MPs can be determined using a prothrombinase assay. The main 
drawback of this approach is that the results are expressed as an area of accessible 
phosphatidylserine and not as amicroparticle concentration, which makes the comparison with 
flow cytometry results hardly feasible [40,29]. Alternatively, a specific antibody can be added 
to quantify a cell-specific MP type. Although this assay is very sensitive to detect weakly 
expressed antigens, the relative non-specificity and non-sensitivity of Annexin V binding for 
MPs makes the technique difficult to use in routine. 
 
Though standard flow cytometers have been extensively used to detect, count, and probe 
antigens at the surface of microparticles, it has to be clear that scattered light cannot be used 
to size microparticles. Most flow cytometers use light sources of wavelengths of 488nm for 
example, which places the diffraction limit at half amicron. In practice, it can be difficult on 
most instruments to discriminate platelets from background noise based solely on scattered 
light, and it is hardly possible to size even smaller objects such as microparticles. Flow 
cytometric analysis of microparticles has thus to rely on specific probes and labels to 
discriminate relevant objects from background noise, but very little can be said about the size 
of the detected objects. A definitive demonstration of this difficulty has been provided by 
Becker et al. who analyzed a calibration bead mixtures ranging from 3 to 8µm and showed 
that the scatter response of commercially available flow cytometers is not necessarily 
monotonous for smaller objects [41]. 
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In this context, the laboratory of Bruce Furie modified a commercial flow cytometer that 
embedded a coulter counter, the Cell Lab Quanta SC from Beckman Coulter, to be able to 
measure objects of a few hundreds of nanometers. Fig. 8 shows the dot plot analysis of 780nm 
fluorescent beads, and authors claim they were able to accurately size particles down to half a 
micron. This modified flow cytometer had been applied to the study of tissue factorbearing 
microparticles in cancer [42,43]. Unfortunately, to the best of our knowledge, this instrument 
remains a unique prototype, whose technical specifications and modifications have not been 
disclosed, making the evaluation of its possibilities hard to truly evaluate. More recently, 
Lawrie et al. [44] tested two commercially available dynamic light scattering instruments (the 
Zetasizer Nano S from Malvern Instruments Ltd., and the N5 submicron particle Size 
Analyser from Beckman Coulter) to size microparticles from fresh frozen plasma. Whereas 
both instruments were able to correctly size calibration beads, they showed ambiguous results 
when applied to microparticles from fresh frozen plasma: it seems that these instruments are 
more adapted to study objects with sharp monodisperse size distributions than biological 
material with broad and overlapping size distributions. Nevertheless, the availability of such 
instruments as well as their lower costs compared to high-resolution flow cytometers might 
make them interesting complementary tools in microparticle research. 
 
Fig. 8. 
Correlation between protein 
titration and microparticle 
concentration. Different markers 
correspond to different samples, 
the coefficient of correlation 
according to Bravais–Pearson test 
is R = 0.85. 
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Microparticle proteomics 
Recent advances in proteomics and new available techniques could play an important role in 
order to elucidate the exact roles of MPs studying their protein content. It is beyond the scope 
of this review to detail the particular biological results obtained by different studies, which are 
highly dependent on the cell type under study. In this section, we would rather insist on 
methodological aspects and difficulties that are shared by all investigators working on 
microparticle proteomics. Numerous publications describe microparticle proteomic studies 
[45–49]. To the best of our knowledge, most studies have adopted the same workflow for 
proteomic analysis of microparticles. First microparticles are pelleted by ultracentrifugation as 
discussed above, then diluted in a standard buffer (e.g. PBS) for protein titration by classical 
assays such as Bradford. In our hands, there appeared to be a correlation between protein 
concentration and microparticle concentration (coefficient of correlation (Bravais–Pearson): R 
= 0.85), as shown in Fig. 8, indicating that in terms of protein quantity, microparticles of 
various RBC origins (e.g. from RBCs stored in different additive solutions, or of different 
storage duration) are relatively homogeneous.  
Because microparticles are not amenable to straightforward lyses such as hypotonic shocks or 
freeze/thaw cycles, most studies have adopted the same protein solubilization protocol: 
microparticles are directly solubilized in one-dimensional gel electrophoresis (1D-GE) 
loading solutions such as Laemmli, containing SDS and a reducer such as dithiothreitol, and 
proteins are separated by 1D-GE, protein bands are cut, and further digested by a proteolytic 
enzyme (usually trypsin) and identified by various mass spectrometry techniques. The clear-
cut advantage of this technique compared to gel-free approaches is that to some extent 1D-GE 
is compatible with the analysis of hydrophobic proteins. This feature is important since 
microparticles, due to their formation mechanism and surface-to-volume ratio are expected to 
contain more membrane proteins with respect to their total proteome compared to their parent 
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cells. For example, using this approach, Miguet et al. found 34% of plasma membrane 
proteins in the microparticles derived from malignant lymphocytes, which is twice as much as 
in their parent cells [48]. Additionally, in our experience, 1D-GE provides another level of 
information that is complementary to the MS/MS identification of proteins based on a few 
peptides: the molecular weight of the identified protein can indeed be deduced from its 
position on the gel, which can sometime provide some indications about protein processing. 
For example, in a slice of a RBC microparticle separated by 1D-GE, we identified proteins 
such as Band 3 and RhD protein (see Fig. 9) that are much larger than the gel band in which 
they were found, suggesting that truncation or cleavage has occurred. Conversely, we also 
found proteins, such as haemoglobin subunits, that are much lighter than the gel band in 
which they were found, which is consistent with the fact that haemoglobin tends to be cross-
linked to cytoskeleton proteins, especially under stress conditions [50]. The observation of 
such variance between observed and expected molecular weights has already been repeatedly 
reported in RBC proteomics: for example, Pasini et al. reported that such proteins originate 
either from organellar proteins, in which case they are most likely to originate from 
degradation products processed during cell maturation (case for proteins with lower molecular 
weight than expected), from ubiquitinated proteins targeted for degradation (case for proteins 
with higher molecular weight than expected), or from detergent- and reducing agent-resistant 
macromolecular assemblies, such as cytoskeletal assemblies [51]. 
Interestingly, following the same approach Bosman et al. differentially analyzed so-called 
microvesicles, isolated from the supernatant of RBCs at 40,000×g, and so-called 
nanovesicles, further isolated by centrifugation at 100,000×g [6]. Though this differential 
isolation relies on a somehow arbitrary criterion, the differential proteomic analysis 
performed by the authors showed marked differences between micro- and nanovesicles: main 
protein categories found in microvesicles are membrane and cytoskeletal proteins as well as 
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metabolic enzymes, whereas nanovesicles are particularly enriched in uncategorized proteins. 
On the contrary, whereas immune proteins such as immunoglobulins and complement 
proteins are almost absent from RBC membranes and microvesicles, they are clearly 
identified in nanovesicles. This differential protein sorting between micro- and nanovesicles 
might indicate that the two populations are generated by different mechanisms and play 
different roles in RBC ageing and stress response.  
Following the observation that microparticle proteins are not necessarily found at the right 
position on a 1D gel, and thus that some important protein processing occurs at the 
microparticle level, we undertook a systematic effort to separate the microparticle proteome at 
the protein level by two dimensional gel electrophoresis (2D-GE) so as to be able to analyze 
differentially processed proteins. Unfortunately, 2D-GE is poorly amenable to the analysis of 
membrane and hydrophobic proteins. Hence following the work by Rabilloud et al. about 
membrane proteins solubilization for 2D-GE [52,53],we solubilized aMP pellet in urea, 
thiourea, DTE, pharmalyteTM and detergent (either CHAPS, ASB-14 or Brij 35). The protein 
mixture was then fractioned by OFFGEL electrophoresis and the fractions corresponding to 
pH 3–7 were pooled, so that haemoglobin was left in the most basic fractions. Following this 
haemoglobin depletion step, proteins were separated by 2D-GE with the detergent of choice. 
A typical 2D gel is shown in Fig. 10 (where Brij 35 was used to solubilizemembraneproteins). 
Whereas some haemoglobin can still be observed at the lower right corner of the gel, as 
pointed by several authors [54–57], haemoglobin depletion helps resolving more spots 
compared to the unfractioned sample. Moreover, the picture obtained by this differential 
solubilization strategy is dramatically different from the one obtained by using classical 
protocols (e.g. CHAPS solubilization). 
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Fig. 9 Proteins identified from a 25–35 kDa region of a 1D-GE of RBC membranes and RBC 
microparticles by MALDI-TOF/TOF mass spectrometry. Greyed proteins have a molecular 
weight that does not correspond to their position on the gel. 
 
 
 
 
Fig. 10. 2D-GE separation of 100µg erythrocyte 
microparticles proteins beforehand depleted in 
haemoglobin by OFFGEL electrophoresis. The 
first dimension is a 4–7 linear pH gradient, second 
dimension is a 4–12% gradient polyacylamide gel. 
In the present gel, Brij-35 detergent was used to 
solubilize membrane proteins. 
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Conclusion 
 
There has been increased interest in the recent years in microparticle proteomics, mainly 
because microparticles are shed in biological fluids (in blow flow or in urine) by their parent 
cells and are thus readily accessible for analysis. Furthermore, they are in many situations 
hallmarks of cell lesion, and their proteomic analysis promise to shed some light on the 
biology of their parent cell, which may ultimately provide some valuable biomedical 
information. Somewhat differently, in the field of transfusion medicine, RBC and platelet 
microparticles are inherent parts of the blood product delivered to patients, and there is little 
chance that their presence be totally innocuous. However, proteomic analysis of 
microparticles turned out to be much more difficult than expected, mainly because of pre 
analytical caveats. As we have attempted to demonstrate in this review, every single 
manipulation of the sample might have a direct influence on its microparticle content. Factors 
such as temperature, the dilution solution used, the way solutions are mixed, are crucial in the 
determination of microparticle concentration, and thus in the subsequent proteomic analysis. 
Additionally, the small size of microparticles makes their detection and sizing very difficult 
by standard techniques such as flow cytometry. The numerous caveats we tried to exemplify 
in this paper make the comparison between different studies almost impossible, and this is the 
reason why so much debate exists in the literature about the microparticle properties and 
functions. However, there is no doubt that proper control of the pre-analytical factors, as well 
as proper reporting of the methods used, will prompt sound and valuable insights into RBC 
biology through proteomic analysis. 
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Introduction 
 
More and more knowledge on blood microparticles (MPs) has been accumulated this last 
decade. However the role(s) of those small phospholipid vesicles still remain unclear. MPs, 
also named microvesicles or ectosomes, range from 0.1 to 1 m in size, and are released in 
blood flow by various types of cells 
1
. They are found in healthy individuals as well as in 
patients suffering from different diseases. The release of MPs is a highly controlled process 
prompted by various stimuli such as shear stress, complement attack, agonist (or pro-
apoptotic) stimulation or damage 
1,2
. If MPs were first described as cellular debris without any 
biological function 
3
, nowadays they are known as cellular effectors involved in numerous 
physiological processes such as haemostasis and inflammation 
4
, transfer of surface proteins 
5
, 
angiogenesis 
6
 or apoptosis 
7
. Moreover, there is a link between MPs and several diseases 
such as thrombocytopenic disorder 
8
, thrombosis 
1
, cardiovascular diseases 
9
, diabetes 
10
, 
sickle cell disease 
11
, haemolytic anaemia 
12
 or sepsis 
13
, where an increase of the number of 
MPs in plasma has been demonstrated. Interestingly, a decrease in MPs numbers in plasma of 
patients presenting with the Scott syndrome, a rare bleeding disorder, has been reported 
14
. 
MPs are also present, and accumulate, in blood products such as erythrocyte and platelet 
concentrates during storage 
15-17
. Because the surface of MPs is made of negatively charged 
phospholipids, they may play a role in the coagulation cascade. Therefore, the purpose of this 
paper is to review the potential procoagulant effect of erythrocyte MPs and thus, their 
potential adverse effect after blood transfusion. 
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Microparticles and Coagulation 
Blood coagulation is an essential mechanism that prevents bleeding; this highly controlled 
process is carefully regulated in order to maintain blood circulation in case of injury while 
preventing vessels obstruction by clot formation. Coagulation factors, calcium ions and 
procoagulant membrane surfaces are the primary components involved in coagulation 
activation. In eukaryotic cells, including blood cells, it is established that neutral 
phospholipids (such as phosphatidylcholine) are mainly present on the outer membrane, 
whereas negative phospholipids (such as phosphatidylserine) are at the inner side of the 
membrane. Concerning blood cells various translocases are activated upon stimulation and 
phospholipid asymmetry is disrupted. Phosphatidylserine (PhSer) is externalized, modifying 
the neutral membrane charge into negative 
18
. Activated blood cells and their MPs expose 
negative membrane and are thus thought to be procoagulant. The presence of negatively 
charged phospholipid membranes and calcium ions is required for the assembly of 
coagulation complexes such as tenase or prothrombinase. The role of tenase complex is to 
convert factor X (FX) into activated factor X (FXa), in both extrinsic and intrinsic pathways. 
The extrinsic tenase complex is composed of tissue factor (TF) and FVIIa 
18
 whereas the 
intrinsic tenase is composed of co-FVIIIa and factor FIXa 
19,20
. The function of 
prothrombinase, constituted of co-FVa and FXa, is to convert prothrombin into thrombin. 
FIXa and FXa can convert their substrate without their respective cofactors, however 
negatively charged membranes catalyses the reaction, for example 3x10
5
 fold faster in the 
case of prothrombinase 
21,22
. Figure 1 presents the possible site of actions of MPs on the 
coagulation cascade. The importance of negative phospholipids is to facilitate complex 
association, speeding up their association by around 1000 fold for efficient haemostasis 
23
. 
Because express PhSer on their membrane, they could contribute to coagulation by providing 
catalyzing negatively charged membranes. It has been demonstrated that platelets-derived 
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MPs have from 50- up to 100-times more procoagulant activity than platelets 
24
. MPs 
membranes support more efficiently thrombin formation than platelet membrane when 
corrected for unit of surface, at least in vitro 
4,25
. Not only platelet MPs are involved in this 
process, but erythrocyte MPs and other MPs have also a procoagulant activity through their 
negatively charged membrane as well 
1,11,26
. 
Although controversial, some authors claim that MPs support clotting not only through their 
negatively charged membranes, but also by expressing an inactive form of tissue factor (TF) 
on their surfaces. The origin and mechanism of action of blood-born TF is still subject to 
debate, nevertheless authors have suggested that MPs may be a reservoir of blood-born TF 
27
. 
Furie et al delineated a “microparticles accumulation pathway” as part of the coagulation 
cascade 
25
. According to this model, some monocyte-derived MPs expressing TF in an 
“inactive” form bind to a forming clot in vessels and display active TF that helps to amplify 
coagulation. In an other hand, Connor et al proposed an activated factor X assay to measure 
clotting time of various samples containing MPs and their results show that there is a 
correlation between the number of MPs and clotting time; interestingly enough, the assay was 
insensitive to the presence or the absence of TF 
28
. Other studies mention the presence of TF 
on endothelial-derived MPs 
29
, platelet-derived MPs 
30,31, or even on erythrocyte-derived MPs 
32
, while some others did not detect any MPs-exposing TF 
11
. All these pieces of evidence are 
difficult to explain, in particular because results often depend on the study design, methods of 
MPs isolation, and various pre-analytical factors; therefore one cannot exclude that 
discrepancies might result from different experimental methodologies 
33
. 
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Figure 1 
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Figure 1: General scheme of experiments on blood microparticles.  
Proteomics, coagulation tests, flow cytometry and imaging by microscopy are the most common 
approaches to investigate microparticles. It is possible to study microparticles from various 
origins (whole blood, plasma as well as platelet or red blood cells concentrates). Of note, agonists 
such as calcium ionophore or protaglandine E2 are frequently used to induce cells microparticles 
release. Various centrifugation steps may be used to further isolate microparticles depending on 
the experiment condition. Indeed, in proteomics or coagulation tests, it is important to work on 
“purified” microparticles.       
 
- Proteomics approach: The characterisation of microparticle proteins is aimed to gain insights 
on the various biological processes involved in their production and function. Generally, after 
isolation of microparticles, they are directly solubilised in one-dimensional gel electrophoresis 
buffer. After migration and staining, protein bands are excised, digested by a proteolytic enzyme 
(usually trypsin), and identified by various mass spectrometry techniques. One-dimensional gel 
electrophoresis allows separating membrane as well as soluble proteins with a good compatibility 
to mass spectrometry analysis. Two-dimensional gel electrophoresis allows a better protein 
sorting, but this technique is poorly amenable to analysis of hydrophobic protein. In all technique, 
elimination of very abundant proteins, such as haemoglobin should be performed to detect the less 
abundant ones. This could be done by chromatography, “off gel electrophoresis” or by using 
“proteominer” techniques. As for one-dimensional gel electrophoresis, it is possible to excise 
spots of interest for identification by mass spectrometry. By using approaches described by 
Rabilloud et al 58 it is possible to improve the migration of hydrophobic proteins after two-
dimensional gel electrophoresis, but the drawback of such approach is its lower compatibility with 
mass spectrometry. Therefore, most microparticle protein lists published were established using 
one-dimensional gel electrophoresis techniques followed by mass spectrometry. By this approach, 
we identified the presence of RHCE proteins in erythrocyte microparticle membranes, as showed 
on the mass spectrometry results presented in the scheme (a peptide corresponding to amino acids 
401-417 from the RHCE protein was identified).    
 
- Coagulation approach: There are more and more evidences that microparticles are involved in 
coagulation. Therefore, different assays could be done on microparticles. Standard clinical 
coagulation tests could be done such as determination of the thrombin time, the activated partial 
thromboplastin time or new available tests allowing determination of FXa. These approaches will 
allow determining at what level microparticles are involved in clotting.  
 
- Flow cytometry approach: This is one of the most frequently used techniques to analyse 
microparticles. Indeed, it allows analyzing thousands of microparticles in one sample with 
determination of different markers and enables semi-quantitative analysis at the same time. For 
the semi-quantitative analysis, a precise number of fluorescent beads are used to determine the 
number of microparticles in a sample. Using the same number of beads, it is thus possible to 
compare the number of microparticles among different samples. Fluorescent cell-specific 
antibodies or annexin V (a phosphatidylserine marker) are used to tag microparticles and to 
differentiate them from the rest of the events. Using the antibody of choice and according to the 
type of microparticles, it is to detect and highlight surface antigens such as CD-235a, CD41, or 
even RH2 or RH4 (as presented on the scheme).  
 
- Imaging approach: Observation of microparticles by microscopy give information about their 
size and shape. Though numerous steps of preparation, scanning electron microscopy  allows 
observing if microparticles are homogeneous in size or not. By confocal differential interference 
contrast microscopy, it is possible to observe forming microparticles from echinocyte.   
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Microparticles and hypercoagulability  
Hypercoagulability state is associated with an increased risk of fibrin deposition in blood 
vessels, which could result in thrombus formation 
34
. Hypercoagulable state has been often 
observed in case of chronic haemolytic anaemia‟s (sickle cell disease, thalassemia, 
paroxysmal nocturnal haemoglobinuria, autoimmune anaemia) 
35
. Frequently, there are 
erythrocyte membrane alterations with accumulation of negative procoagulant membranes in 
blood flow, platelet activation, and a decreased level of anticoagulant proteins, amplifying the 
risk of thrombosis 
35. In thalassemic patients, the main determinant of the thrombotic risk 
seems to be related to altered red blood cell membranes as well as to platelet activation, but 
not to plasma protein abnormalities 
36
. Erythrocyte membrane alterations leads to the 
exposure of PhSer on the outer layer, cytoskeleton cleavage, membrane budding and release 
of MPs 
8
. An elevated number of MPs in blood flow has been reported in patients suffering 
from different vascular diseases 
1
. Consequently, MPs could have an essential causal role in 
hypercoagulable states, as reported by Van Beers et al in sickle cell disease 
11
. The authors 
showed that, while the number of platelet-derived MPs was stable, there was an increase in 
erythrocyte-derived MPs during crisis compared to steady state. 
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Microparticles and red blood cells storage 
Modification, alteration or even degradation of erythrocyte concentrates (ECs) occurs during 
storage (a phenomenon called the storage lesions) 
7,37
, and accumulating MPs have been 
considered as being one of the expression of storage lesions 
15
. Red blood cells‟ ageing in 
blood bank conditions clearly differs from physiological in vivo ageing. Undeniably, 
conditions to which red blood cells are exposed during storage such as temperature and nature 
of the medium are dramatically different from in vivo conditions. Erythrocytes degrade and 
loose efficiency during storage. Indeed, erythrocytes change shape; their membranes become 
more rigid and there is a disruption of phospholipids asymmetry and release of fragments and 
MPs 
37
. In addition, during the conservation of erythrocyte in plastic bags, not only 
physiological alterations occur, but also biochemical changes in the storage medium 
principally due to red cells metabolism. These modifications, physiological and biochemical 
are part of the storage lesions. There is an increase in the concentration of lipids, free 
haemoglobin, potassium, lactate and in contrast a reduction of pH, glucose, 2,3-
diphosphoglycerate, sodium or adenosine triphosphate 
38
. For example diminution of glucose 
and increase of lactate concentration reflects red blood cells glycolysis. 
In blood flow, MPs are rapidly removed in the liver by Kupffer cells 
39
. Release of MPs 
occurs throughout erythrocyte lifespan 
39
 and continues during storage, therefore they 
accumulate during storage 
17
. Precise reasons of erythrocyte vesiculation are not elucidated, 
however MPs is a possible mechanism preventing red blood cell removal. MPs may help to 
clear away the C5-9 complement attack complex, band 3 neoantigen, IgG or other potential 
harmful agent from the membrane, when the erythrocyte is still viable 
40-42
. In addition, MPs 
formation could be a mechanism involved to clear out methaemoglobin which is no more 
functional 
37
.  
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The precise consequences of storage, including storage lesions and MPs release, on 
transfusion efficiency are not clearly understood, and relatively little is known about their 
molecular bases and even less about their possible biomedical consequences on recipients. 
There is accumulating evidence that receiving “old” blood is not as advantageous as receiving 
fresher blood. In 2008, Koch et al showed a link between the age of the transfused ECs and 
post-transfusion complications. They claimed that life expectancy at 5 years was better for 
patients who received fresher blood (ECs stored for less than 14 days) as compared to older 
blood (stored for more than 14 days) in the course of cardiac surgery 
43
. A recent study by 
Spinella et al concluded that ECs stored for more than 28 days was associated with an 
increased incidence of deep vein thrombosis and death from multi-organ failure 
44
. Other 
studies on post-transfusion complications or mortality and storage time were also published 
and controversial 
45-47
. However, although these studies raise important questions about 
transfusion safety and storage lesions, they are subjected to many discussions 
48-51
.  
Due to the fact that transfused people are sick and polytransfused recipients are often in poor 
condition, it is difficult to attribute clearly an event to transfusion rather than on the clinical 
situation of the recipient. In a recent review, Zimrin and Hess analyzed several papers on 
clinical studies examining the effect of storage of red blood cells in transfusion and concluded 
that well designed epidemiologic studies are needed to demonstrate that a clear clinical effect 
may be due to ECs storage lesions. Despite the lack of conclusive evidence that storing blood longer is worse, it 
is current practice to transfuse fresher blood to patient considered at high risk (such as in 
neonatology for example or cardiac surgery). 
As stated before, MPs may have procoagulant activities; therefore, we may reasonably 
suggest that transfusion of “older” ECs containing a high number of MPs could increase the 
risk of adverse reactions, by inducing a hypercoagulable state leading to thromboembolic 
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complications. Inversely, in many situations requiring blood transfusion, a hypercoagulable 
state may be useful to diminish or even helping to stop the bleeding. 
 
 
Table 1: Overview of studies on proteins of microparticles reported in the literature  
 
  
Type of 
MPs 
Theme  Technique   Main Results Ref. 
Red blood 
cells 
Red blood cell 
membranes and MPs 
proteome 
Centrifugation,                      
LC-MS/MS 
Storage-dependent changes in the RBC 
membrane proteins. MPs display similar 
change in their protein composition during 
storage. 
53 
Red blood 
cells 
MPs during storage of 
EC  
Centrifugation, 
Flow cytometry,         
1 D SDS PAGE, 
Western Blot, 
MALDI-MS 
Number of MPs increase during storage. 
Proteomic analysis revealed changes of 
protein expression comparing MPs to 
erythrocyte membranes. 
17 
Plasma Proteome of Plasma 
MPs 
Centrifugation, 
Flow cytometry,           
2 D-GE,     
MALDI-MS 
Comparison between plasma and MPs 2D-GE 
and LC-MS/MS to list MPs proteins. From the 
spotted sample, 83 different proteins and 
their respective isoforms were identified in 
which 13 have never been reported in human 
plasma.  
55 
Platelet  Proteome of platelet 
MPs 
Centrifugation,       
1D SDS-PAGE,        
LC-MS/MS 
The identification of 578 proteins of platelet 
MPs was accomplished among which 380 
were not identified previously in platelet 
proteome  
52 
Endothelial Proteome of endothelial  
procoagulant MPs 
Centrifugation,         
1D SDS-PAGE,        
LC-MS/MS 
This study describes the protein composition 
of endothelial cell MPs. Among proteins, 
presence of metabolic enzymes and bioactive 
effectors has been evidenced.  
56 
Malignant 
lymphocyte 
Characterization the T-
lymphocytes MPs 
proteome 
Centrifugation,         
1D SDS-PAGE,        
LC-MS/MS, 
MALDI-MS 
In total, 390 proteins were identified, 34% of 
those proteins were from plasma membrane 
among which proteins involved in 
hematopoietic clusters of differentiation. 
57 
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Proteomics and microparticles analysis 
 
Recent advances in proteomics provide new tools allowing studying protein content of MPs in 
order to elucidate their exact role. Several publications are focused on proteomics of MPs 
derived from various type of cells (see table 1). Results are different according to the MP cell 
types and the methodological aspects. To the best of our knowledge, most studies have 
adopted the same workflow for proteomic analysis of MPs as shown in the “proteomic” part 
of figure 1 (excepting for the initial sample that is not ECs in all cases). Briefly, once isolated 
by centrifugation, MPs are directly separated by one-dimensional gel electrophoresis (1D-GE) 
and finally protein bands are excised, and further digested by a proteolytic enzyme (usually 
trypsin) and identified by various mass spectrometry techniques. The main advantage of this 
technique is the compatibility with the analysis of hydrophobic proteins in contrast to two 
dimensional electrophoresis gel (2D-GE) approaches. Among different proteomic studies on 
MPs, various lists of MP proteins have been established. Mapping of MP proteins involved in 
coagulation is still lacking. In the study of platelet MPs proteome by Garcia et al
52
 when the 
list of proteins is submitted to a QuickGO search with the GO reference “blood coagulation”, 
12 proteins out of 578 were found to be involved in blood coagulation. Recently, Bosman et 
al 
53
 established a reference proteome of red blood cells MPs. When the protein list was 
submitted to a QuickGO search with the same parameters as mentioned above, 5 out of 308 
proteins were involved in coagulation, namely phospholipid scramblase 1, plasminogen 
precursor, fibrinogen beta chain precursor, complement component C9 precursor and beta-2-
glycoprotein 1. Except for phospholipid sramblase 1, proteins were neither identified in red 
blood cells membrane proteome established by Bosman et al 
53
 nor by Pasini et al 
54
. As 
procoagulant proteins of MPs were not found on red blood cells, we could hypothesize that 
those proteins were either of plasmatic origin with a non-specific binding to MPs or were 
proteins present on red blood cell membranes, but enriched on MPs microdomains.  
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Discussion  
The important issue raised by the presence of MPs in blood products is to determine their 
exact involvement for the recipient. It has been demonstrated that MPs are present in blood 
products, and that they number increases during storage. Series of articles and reviews were 
published on the association between red cell storage duration and complications after 
transfusion. However few of them mentioned MPs as potential cause of these complications. 
Therefore, there is an urgent need of large clinical studies with the aim to determine precise 
effects (if any) of MPs in blood recipients. Furthermore, it is important to determine how MPs 
are involved in the coagulation cascade, by either passively acting by providing additional 
negatively charged membrane surface, or rather by allowing the expression of TF or other 
proteins implicated in the coagulation process. Furthermore, studies of MPs from platelets, 
endothelial cells or monocytes and comparison with EC-derived MPs are needed. Proteomic 
analysis, as well as quantitative proteomic evaluation of they protein content will open new 
avenues in haematology, because it will help to decipher the complexity of the 
hypercoagulable states and the effect of EC transfusion in routine clinical practice. Combining 
various approaches that are haemostatic investigations, MPs characterisation either by 
cytometry or by proteomics, clinical studies will certainly help to secure transfusion medicine. 
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Summary  
 
Microparticles are small phospholipid vesicles of less than 1 µm shed in blood flow by 
various types of including red blood cells. They are involved in many biological and 
physiological processes including haemostasis. Elevated number of microparticles in blood 
flow is often observed in various pathological situations. 
Erythrocyte-derived microparticles accumulated in erythrocyte concentrate during their 
storage time. Their exact role being not elucidated, they are considered as storage lesion.  The 
aim of this study was to evaluate the impact of erythrocyte derived microparticles in 
coagulation.  
Using calibrated automated thrombogram, it has been demonstrated that erythrocyte derived 
microparticles isolated from red cells concentrates are capable not only to support thrombin 
generation, but also to trigger thrombin generation in assays. As the impact of those 
transfused microparticles is unknown on recipients, clinical study is needed to increase 
knowledge in the field of transfusion medicine.  
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Introduction 
 
Microparticles (MPs) are small phospholipid vesicles of less than 1 µm circulating in blood 
flow, typically 0.15 µm for erythrocyte derived MPs (EMPs). They are heterogeneous in size, 
phospholipid content and surface proteins according to the cell they derived [14]. MPs are 
observed in healthy individuals and their increase has been observed in a variety of diseases 
[14, 23-27]. In contrast, a very low number of MPs has been observed in patients presenting 
with Scott syndrome, a rare bleeding disorder associated with apparent normal platelet 
function and coagulation factors level [28]. 
The release of MPs is a controlled process, triggered by various stimuli, including cell 
stimulation, shear stress or apoptosis [15]. If MPs have been first described as “cell 
dusts”[20], they are now recognized as being involved in a broad spectrum of biological 
activities [15, 22, 71, 72] including thrombosis and haemostasis [14, 21].  
In contrast to their parental cells, the majority of MPs exposes negatively charged 
phospholipids on their outer membrane (mainly phosphatidylserine). As negatively charged 
phospholipids are required for the assembly of coagulation complex such as tenase or 
prothrombinase, MPs are thus thought to be procoagulant [16, 73, 74]. Indeed, it has been 
demonstrated that platelet derived MPs have from 50 up to 100 times more procoagulant 
activity than platelets [55]. As EMPs presents negatively charged membrane as well, those 
last could thus support coagulation [56].  
During  ex vivo storage  of  red blood cells (RBCs), numerous biochemical changes occur 
such as for example pH acidification and increase in free haemoglobin [41]. Those changes 
commonly referred as “storage lesions” [3] also include RBC modifications, such as increase 
in membrane rigidity, lipid rafts rearrangement, disruption of phospholipid asymmetry and 
MPs release. It has been demonstrated that EMPs accumulate during storage [29], with great 
variation of their number from an erythrocyte concentrate (EC) to another, most likely due to 
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the donor, conservative solution or even the preparation methods [62]. EMPs transfused 
within the EC could represent an additional source of negatively charged phospholipids and 
the impact on transfusion is still unknown [75].  
The aim of our study is to evaluate the impact of EMPs isolated from ECs on transfusion 
studying their ability to support or trigger thrombin generation (TG) in vitro.  
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Materials and methods  
Erythrocyte concentrates 
 
ECs were provided and prepared at the Lausanne blood bank according to the standardized 
procedure. Briefly, 450 ± 50 ml of whole blood was drawn by venipuncture and collected in 
blood bags (Fenwal, Lake Zurich, IL, USA) containing citrate–phosphate–dextrose 
anticoagulant solution. RBCs were separated from platelet, anticoagulant solution and plasma 
by centrifugation and directly resuspended in 100 ml of preservative solution sodium–
adenine–glucose–mannitol. Leucocytes were then removed by filtration. ECs were stored up 
to 42 days at 4°C.  Only outdated ECs that were not transfused within 42 days of storage, but 
less than 45 days, were used for EMPs isolation.     
Plasma 
 
2.7 ml of venous blood were drawn with a 21-G needle directly into citrated tube (Sarstedt, 
Leicester, UK) containing 0.3 ml of  sodium citrate and corn trypsin inhibitor (CTI) at a final 
concentration of 10.6 mM and 1.6 µM in whole blood, respectively. CTI inhibits intrinsic 
coagulation pathway at a concentration of at least 1µM in platelet-rich plasma (PRP) [76]. In 
addition, it allows reducing imprecision when measuring endogenous thrombin potential 
(ETP) by Calibrated Automated Thrombogram (CAT) in plasma samples at low TF 
concentration [77]. In order to avoid withdrawing TF and factor XII, light tourniquet and 
minimal suction was applied, and the first tube was not used for coagulation assay. Three 
sequential centrifugations (2 x 1500 g and 1 x 18‟000 g) were proceeded in order to remove 
cells and the majority of MPs from plasma. For all experiments, only fresh plasma was used, 
and it remained at room temperature during sample preparation. As clotting factor 
concentration and thus haemostasis differ from one person to the other, in some experiment, 
pool of plasmas was used to avoid single person variability. For all CAT tests presented in 
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results, the same pool of fresh plasma from seven volunteers was employed. For western 
blotting, plasma samples were passed through ProteoMiner
TM
 columns (Biorad, Hercules, 
CA, USA) allowing to enrich low abundance proteins and compression of dynamic range of 
protein concentration in samples [78]. 
Microparticles Preparation  
 
Isolation of EMPs 
EMPs released during storage were separated from red blood cells by two successive 
centrifugations in 50 ml tubes of ECs at 1000 g, 10 minutes and 2000 g, 5 minutes at room 
temperature. Supernatant was collected and then another centrifugation at 18‟000 g for 30 
minutes at 4°C was performed. The supernatant was removed and the pellet was resuspended 
in filtered 0.9% NaCl solution. In order to avoid putative polymorphism effect, pools of EMPs 
issue from 4 different ECs were used. As EMPs also have blood group antigens on their 
surfaces [75], only group O concentrates were employed to avoid eventual agglutination 
reactions.      
 
Tissue Factor coated EMPs 
In order to obtain “artificial” tissue factor (TF) bearing EMPs (EMPs-TF) serving as a model, 
200 µl of EMPs previously obtained were incubated with recombinant tissue factor (rTF) at a 
concentration of 100 nM at room temperature for 3 hours on constant agitation. EMPs were 
quantified by flow cytometry as described thereafter. Excess of rTF was removed by two 
washing steps consisting in centrifugation at 18‟000 g, 30 min at 4°C and the pellet was 
resuspended in 200 µl of a 0.9% NaCl solution.  
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Flow cytometry  
Samples of MPs were analyzed on a FACScalibur flow cytometer with CellQuest pro 
software (BD Biosciences, Franklin Lakes, NJ, USA). Flow cytometer was calibrated with 
CaliBRIT™3 kit (BD Biosciences) containing different fluorescent beads. Size events were 
defined using flow cytometry size beads of 1–1.4 μm (Spherotech, Lake Forest, IL, USA). 
Each antibody for flow cytometry was purchased at BD Pharmingen (San Diego, CA, USA). 
For MPs count, 5 μl of EMPs samples or fresh pooled plasma were incubated with 1 μl of 
Fluorescein isothiocyanate (FITC) anti-human CD235a (anti-human erythrocyte) and/or 1 μl 
of phycoerythrin (PE) PE anti-human CD142 (anti-human TF). After 20 minutes in the dark 
on constant shaking, 400 μl of PBS were added and flow cytometry analysis was carried out 
within 30 minutes in a Trucount™ tube (BD Biosciences). In order to avoid modifying the 
count, no centrifugation step to remove the excess of antibody was done.  
 
Western blotting  
Depending on the experimental conditions, from 5 to 40 µg of various proteins samples 
(EMPs, EMPs-TF or plasma) were loaded onto a 4–12% NuPAGE Novex Bis-Tris 
polyacrylamide gel (Invitrogen, Carlsbad, CA, USA) while from 0.0034 to 340 ng of pure rTF 
were load as positive control. After migration, carried out at constant voltage (150 V), 
proteins were transferred to Hybon-LFP polyvinylidene fluoride membranes (GE healthcare, 
Uppsala, Sweden) using a Novex blot module (Invitrogen) for 1 h 45 min at fixed voltage (30 
V), according to the manufacturer‟s instruction. Membranes were then strained in Ponceau 
red to control if protein transfer occurred. After transfer, blotted membranes were soaked 
overnight in blocking solution with PBS, 0.1% Tween-20 (v/v), 5% milk and 1% bovine 
serum albumin (BSA) (w/v). Western blots were done with rabbit anti-human TF (American 
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Diagnostica, Stamford, CT, USA) at a dilution of 1:500. The goat anti-rabbit horseradish 
peroxidase conjugated secondary antibody (Dako, Baar, Switzerland) was used at a dilution of 
1:10‟000. Subsequent visualization was performed using enhanced chemiluminescence (GE 
Healthcare). The signal was finally captured using X-ray film. 
 
Transmission Electron Microscopy and Immunogold Labelling   
EMPs and EMP-TF samples were resuspended in PBS-BSA 1% (W:V) buffer and centrifuged 
at 18‟000 g, 15 minutes. EMPs or EMPs-TF where then incubated for 1 h in PBS-BSA 1% 
with rabbit anti-human TF (American Diagnostica) at a dilution of 1:25. EMPs were washed 
twice in  PBS-BSA 1%, and centrifuged at 18‟000 g, 15 minutes. Then, samples were 
resuspended in PBS-BSA 1% with gold labelled secondary anti-rabbit antibody (Sigma, Saint 
Louis, MO, USA) for 30 minutes. Samples were washed twice in PBS-BSA 1%, at 18‟000 g, 
15 minutes and fixed in glutaraldehyde 2.5% (V:V) solution. Samples were washed twice in 
H20. Sample of EMPs of EMPs-TF were absorbed onto grids and transferred onto drop of 2% 
uranyl acetat (W:V) for negative staining. Vesicles were finally visualized with a Philips 
CM100 transmission electron microscope (Philips, Amsterdam, Nederland).   
 
Thrombin Generation with CAT  
Measures of TG have been performed with a CAT following procedure developed by Hemker 
et al [79].  Assays were performed on a FluoroskanAscent plat reader (Thermo Labsystems, 
Helsinki, Finland) and Thrombinoscope software (Thrombinoscope BV, Maastricht, 
Netherlands) as described by the manufacturers. 
For each well, 20 l of EMPs in 0.9% NaCl solution, containing different number of EMPs 
previously quantified by flow cytometry, were added to 60 μl of fresh pooled plasma. Two 
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different reagents were used to initiate TG in the test. PRP-regent (Thrombinoscope BV) 
containing TF and minimal amount of phospholipids was used to highlight the contribution in 
coagulation of additional negative phospholipid membrane provided by EMPs. Note that TG 
is phospholipid dependent [79]. MP-reagent (Thrombinoscope BV) did not contain any TF 
and made the assay specifically sensitive to TF present on the surface of MPs. Thrombin 
Calibrator (Thrombinoscope BV) was used to reduce donor or instrumental variability and 
allow comparing samples. CTI, a strong inhibitor of activated factor XII, was added in plasma 
in order to inhibit intrinsic coagulation pathway and to avoid the interference from in vitro 
contact factor activation. Indeed, in vitro contact activation occurs because factor XII binds to 
negatively charge surface and autoactivates [77]. Anti-human TF (American Diagnostica) was 
also employed as TF inhibitor at a dilution of 1:10 (and thus extrinsic pathway inhibitor) in 
EMPs samples when needed. Thus, 20 µl of PRP-reagent, MP-reagent or Thrombin Calibrator 
(Thrombinoscope BV) were added to 80 µl of each of sample into wells. The plate was then 
set in the fluorometer and after warming, thrombin rate measurement started with the addition 
of 20 µl of Fluo-Buffer (Thrombinoscope BV) containing 100 mM of CaCl2 and 2.5 mM of 
fluorogenic substrat. During the measurement, the program compared the readings of sample 
with reagent and calibrator, calculated all parameters and displayed the concentration of 
thrombin in time. For each sample, 5 wells with the reagent and 2 wells with the calibrator 
were analysed. Data were validated and given as mean of the different wells for one sample 
by the Thrombinoscope software (Thrombinoscope BV). 
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Results 
 
Evidencing TF  
Various attempts to evidence TF on EMPs from ECs have been done. Neither flow cytometry, 
western blotting, nor immunogold allowed to evidenced trace of TF either on EMPs or in 
plasma even when plasma was threaded by ProteoMiner
TM
 technology (Fig 1). With pure rTF 
protein, threshold of detection was around 550 pM (corresponding to a load in gel of 0.34 ng 
of pure rTF). TF was clearly evidenced by all used methods on EMPs-TF (Fig 1). 
 
Intrinsic pathway inhibitor 
Plasma prepared for CAT experiments always contained 1.6 µM CTI, when there was no 
other indication. Flow cytometry also confirmed that there is no more platelet and almost no 
more MPs in three times centrifuged plasma (data not shown). In plasma sample without CTI, 
TG is sometimes observed, typically in one on three assays with a great variability in lag time. 
This is due to in vitro intrinsic coagulation pathway activation [77]. Without addition of 
EMPs in plasma containing 1.6 µM CTI, no TG was observed (Fig 2). No statistically 
differences in ETP were observed in sample with 10‟000 EMPs/µl between plasma containing 
1.6 µM and 3.2 µM CTI, (T-test; P < 0.05) (Table I).     
 
 
Contribution of negative phospholipids from EMPs to support TG 
Using PRP-reagent, contribution of EMPs phospholipids in TG was evaluated. Results 
demonstrate that more there were EMPs in plasma, the greater and faster was TG (Fig 2A). In 
addition, control with demonstrate that there was no significant TG in plasma without EMPs. 
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Contribution of EMPs to trigger TG 
TG was observed when from 5000 EMPs/µl to 20‟000 EMPs/µl were added to plasma, even 
if no TF was added (Fig 3). Note that in plasma with 1000 EMPs/µl, no TG was observed 
(Table I). Thus, without addition of exogenous TF, there is TG in plasma with more than 1000 
EMPs/µl (Fig 3). As positive controls, from 250 to 10‟000 EMPs-TF/µl were used in the 
assay. TG with EMPs-TF was always stronger comparing to EMPs. Additionally, the amount 
of EMPs-TF needed to generate thrombin is much smaller (from 250 EMPs-TF/µl) than with 
EMPs (Fig 3).  
As intrinsic coagulation pathway is inhibited with CTI, anti-human TF was employed to 
inhibit putative plasma TF or EMPs-TF even if no TF was evidenced in those samples. In this 
way, both coagulation pathway triggers are inhibited. Interestingly, TG was not inhibited 
when EMPs were added to plasma containing anti-human TF at a concentration of 1:10 
(Table I).  
As positive control, plasma samples with thromboplastin, here Innovin (Siemens 
Healthcare Diagnostics, Marburg, Germany) or with EMPs-TF were tested. For both, rapid 
TG with a high ETP was observed (Fig 2B). Efficiency of anti-human TF was tested in 
plasma samples containing Innovin or EMPs-TF. When Anti-human TF was added to those 
samples, a partial inhibition of TG was observed in the sample with EMPs-TF whereas total 
inhibition was observed in the sample with Innovin (Table I and Fig 2B). These results also 
show that EMPs-TF are strong activator of TG and have a “thromboplastin-like effect”.   
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Discussion 
The exact role of EMPs remains unclear, and their function might be most likely multiple. 
This study demonstrated that EMPs are capable to support TG. This is particularly interesting 
in the field of transfusion due to the fact that EMPs are numerous in blood concentrate and 
they tend to increase during storage [29]. A recent study by Sweeny et al suggest that 
“something” in ECs supernatant facilitate TG [80]. We provide evidences that the element 
facilitating TG in supernatant are EMPs.  
 
Results of CAT gave ETP reflecting a measure of global coagulation in a sample. This study 
demonstrates that in CAT test with TF, TG is observed in presence of EMPs in plasma. Thus, 
EMPs could support TG providing negative phospholipids membranes. Additionally, in CAT 
test without TF addition, TG is also observed when EMPs are added to plasma. When CTI 
and/or TF-antibody are added to plasma samples with EMPs, TG is still observed, while no 
TG was observed in plasma samples without EMPs. In positive control, EMPs-TF added to 
plasma, there is a strong and rapid TG comparing to EMPs alone. Indeed, while there is an 
input of TF leading TG in EMPs-TF samples, another mechanism is most likely involved to 
trigger TG with EMPs in plasma. Interestingly, the presence of inhibitors that triggers the two 
coagulation pathways does not affect TG if EMPs are added to plasma. So, as FXIIa or TF are 
not present or inhibited, it could be inferred that EMPs have the capacity to trigger TG by a 
mechanism that appears independent of both intrinsic and extrinsic coagulation pathways.   
It is not easy to decipher find what trigger TG when EMPs are added to plasma. It might 
suggested that the “microparticles coagulation pathway” proposed by Furie et al triggers TG 
[52]. Another hypothesis would be that EMPs carry a cryptic form of TF or that EMPs are 
able to activate cryptic TF in plasma [57, 81]. However, neither in plasma nor EMPs samples 
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TF was evidenced or was below the detection threshold. Moreover, Bosman et al [3] did not 
highlight TF in an extensive study on EMPs proteome. 
As time preceding the thrombin burst or lag-time variations are usually relatively wide when 
testing intrinsic coagulation pathway in vitro [77]. Therefore it could by hypothesized that 
EMPs might support or imitate intrinsic coagulation pathway. It has been demonstrated that 
factor XI could be activate by thrombin in a factor XII independent manner. Thus, EMPs 
could generate subnanomolar amount of thrombin sufficient to activate factor XI resulting in 
the observed thrombin explosion in CAT [77, 82].   
 
According to literature, there is typically around 2000 platelet-derived MPs/µl and 60 
EMPs/µl in PRP [15, 83].  It is considered that PRP reflects the number of MPs in blood flow. 
In ECs, a previous study using the same count method demonstrates that there are from 
around 3300 EMPs/µl ± 1200 at day six and this increase until around 35‟000 EMPs/µl ± 
15‟000 after 42 day of storage [29]. Consequently, in case of massive transfusion, it is likely 
that the total number of EMPs in blood flow of the recipient rise up. As patients undergoing 
cardiac surgery are often massively transfused, an additional source of EMPs is provided by 
blood concentrates [29]. Moreover, it is known that such surgery produce a release of TF in 
patient‟s blood, even if techniques and procedures are developed to reduce this release [84, 
85]. Taking together, it could be thus hypothesized that under certain circumstances, 
transfused EMPs could be involved in TG and could be linked to post transfusion 
complications or adverse clinical outcome.  
 
Several studies have shown a link between storage time of blood products and post 
transfusion complications [4-6]. However, this is still controversial and some recent studies 
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limited this link only under specific circumstances [7-10]. Indeed, meta-analysis failed to 
point out a “cause” of complication after transfusion related to the storage time. As MPs are 
bioactive, it could be suggested  that EMPs are mediators of these complications [11].  
 
In summary, we provide evidence that i) EMPs in plasma are able to induce generation of 
thrombin, ii) this generation is not abolished using anti-TF, iii) thrombin generation is 
enhanced by adding EMPs previously incubated with TF, with an activity similar to that 
observed with thromboplastin.   
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Table I : Endogenous Thrombin Potential (nM.min) are given for the various samples tested 
in calibrated automated thrombogram with MP-reagent. ETP is given in mean ± SD of five 
independent measures (N=5). For each tested plasma sample, table give also concentration of 
Corn Trypsin inhibitor, number of erythrocyte-derived microparticles (EMPs) or tissue factor 
(TF) EMPs (EMPs-TF), addition of Innovin (1:250) or Anti-human TF (1:10).  
 
   CTI [µM] EMPs/µl EMPs-TF/µl Innovin Anti-TF ETP ± SD 
 1.6 - - - - 0  
1.6 1000 - - - 0 
1.6 5000 - - - 962 ±   99 
1.6 10'000 - - - 986 ± 101 
3.2 10'000 - - - 1063 ± 45 
1.6 20'000 - - - 1120 ± 42 
1.6 - 250 - - 1255 ± 41  
1.6 - 1000 - - 1477 ± 91 
1.6 - 10'000 - - 1516 ± 23 
1.6 
 
10'000 - + 1304 ± 42 
1.6 - - + - 1355 ± 46 
1.6 - - + + 0 
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Legend to figures 
 
Figure 1: Attempts to evidence tissue factor (representative experiments)  
Western blotting  
Using anti-human tissue Factor (TF), detection threshold of recombinant tissue factor (rTF) 
by western blot was around 550 pM (0.34 ng). In plasma samples (treated with Proteominer
TM
 
or not), as well as in erythrocyte derived microparticle samples, no TF was detected. In 
positive controls, samples of erythrocyte derived microparticles coated with tissue factor, 
tissue factor was clearly detected.    
Flow cytometry  
(A) Shows event sorted according to their size and shape. Two different regions are 
determined, Region 1 (R1) for Truecount beads and Region 2 (R2) for microparticles count.  
(B) and (C) show event from R2 according to their fluorescence due to the labelled 
antibodies. (B) Shows erythrocyte derived microparticles (EMPs), events are positive for anti-
human CD235a (erythrocyte marker) and negative for anti-human CD142 (tissue factor 
marker). (C) TF coated EMPs (EMPs-TF); events were positive for human CD235a and 5 to 
15 % were positive for anti-human CD142. 
Electron microscopy  
Transmission electron microscopy of erythrocyte derived microparticles (EMPs) and coated 
tissue factor erythrocyte derived microparticles (EMPs-TF); both samples were stained with 
anti-TF followed by immunogold staining. EMPs-TF are labelled (arrow) whereas no staining 
is observed in EMPs.  
 
 
 135 
Figure 2: Measurement of the activity of erythrocyte-derived microparticles (EMPs) using 
thrombin generation assays. In the presented thrombograms, thrombin generation curves are 
the mean of five independent measures, in a representative experiment with pooled plasma 
and pooled EMPs. 
Effect of negatively charged membranes of EMPs on thrombin generation in plasma. (Test 
with PRP reagent, tissue factor (TF) is added to trigger reaction). Thrombin generation was 
observed when EMPs where added to plasma at a final concentration of 1000 EMPs/µl (), 
10‟000 EMPs/µl () and 20‟000 EMPs/µl (). The more there are EMPs, the stronger and 
faster is the TG. In the absence of EMPs in plasma, no significant TG was observed, 0 
EMPs/µl ().      
(B): Effect of EMPs on thrombin generation in plasma (Test with MP-reagent, no addition of 
tissue factor (TF)) No TG was observed in plasma alone, without EMPs (I). EMPs or coated 
TF EMPs (EMPs-TF) are added to plasma at a final concentration of 10‟000 per microliter. 
Plasma with EMPs-TF () or Innovin in the absence of EMPs () are strong activator of 
thrombin generation in the test. Thrombin generation was also observed in plasma sample 
with EMPs (). A partial inhibition of thrombin generation was observed when anti-TF is 
added to EMPs-TF sample (), whereas inhibition was complete when anti-TF was added to 
plasma with Innovin in the absence of EMPs () .  
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 Figure 3 Endogenous Thrombin Potential of erythrocyte-derived microparticles (EMPs) and 
coated tissue factor EMPs (EMPs-TF) at various concentrations.   
Endogenous Thrombin Potential (nM.min) measurements of plasma samples containing 1.6 
µM of corn trypsin inhibitor with the addition of 0 to 20‟000 EMPs/µl () or 0 to 10‟000 
EMPs-TF/µl () in thrombin generation assays with MP-reagent. Each dots represent the 
mean of five independent measures ± SD, N=5. ETP values for each sample are presented in 
Table I.        
 
  
 137 
 
Figure 1  
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Figure 3 
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Avant-propos 
 
Ce chapitre est consacré à des réflexions moins scientifiques, mais plutôt humanistes. Loin de 
moi la prétention d‟être un philosophe ou écrivain, cependant le (jeune) chercheur que je suis 
aimerait partager ses préoccupations et interrogations sur les enjeux et problèmes éthiques que 
l‟on peut rencontrer en transfusion.  
J‟aimerais dédier ce chapitre aux personnes qui nous ont quittées pendant mon travail de 
thèse.  
 
A mon père, Willy Rubin, décédé en 2009  
A Florence Rappaz-Rosset, partie trop tôt en 2010  
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Résumé 
Le don de sang représente un acte solidaire. Il est le plus souvent bénévole et, selon les pays 
et les circonstances, non rémunéré. Face à l‟augmentation des besoins, face aux critères 
d‟exclusion de plus en plus nombreux, face à la dérive sécuritaire et tenant compte des 
modifications des structures de nos sociétés, de nombreux acteurs de la chaîne 
transfusionnelle s‟interrogent sur la valeur du don, sur le sens du bénévolat et finalement sur 
l‟opportunité de rémunérer l‟acte de livrer une partie de soi, non plus comme un don, non plus 
comme l‟expression de l‟altruisme et de la solidarité, mais comme une prestation 
commerciale définie par des règles économiques pouvant inclure ou non des aspects éthiques 
d‟un commerce dit équitable ou non. 
 
Abstract 
Ethical aspects of blood donation are apparently well defined, and in most countries, donors 
are not remunerated. However, in more particularly in countries in which plasma fractionation 
is particularly well developed, the question of a finical compensation is either in discussion or 
is already implemented. What is the truth? What are the ethical considerations that must be 
taken into account when discussing the organization of the blood supply? Health systems have 
developed ethics, known as medical or biomedical ethics. However, economy has also its own 
ethics. How to deal with these realities? Is remuneration of blood an interdict or a modern 
response of the society faced to the necessity of organizing blood transfusion for all people 
needing blood products? 
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Introduction 
Le sang est une ressource précieuse, sa symbolique, son mode de prélèvement et de 
distribution en font un élément unique dans l‟histoire de la médecine et de l‟homme. La 
demande des hôpitaux en produits sanguins labiles a tendance à augmenter d‟années en 
années tandis que le nombre de dons, lui, diminue. 
Lorsqu‟on parle de don du sang, on regroupe deux mots portant des symboliques fortes, 
« don » et « sang ». Selon le Petit Robert « Donner, c‟est abandonner à quelqu‟un, dans une 
intention libérale ou sans rien recevoir en retour, une chose que l‟on possède ou dont on 
jouit ». On trouve également comme première définition dans le dictionnaire Larousse 
« Céder, offrir gratuitement à quelqu‟un quelque chose qu‟on possédait ou qu‟on a soi-même 
achetée à cet effet ». C‟est en général, cette définition qui vient à l‟esprit de la plupart des 
gens. La seconde définition donnée par le Larousse est « Remettre, attribuer quelque chose 
(de l‟argent souvent) à quelqu‟un comme récompense ou comme paiement en échange de 
quelque chose ». Dans ces deux définitions, on observe deux concepts très différents : dans le 
premier on parle d‟offrir, l‟action est dirigée dans un sens unique, dans le second on parle 
d‟échange, l‟action s‟accomplit dans les deux sens. Selon Marcel Mauss, sociologue et 
philosophe français du 20
ème
 siècle, il n‟y aurait pas de don pur ou don totalement altruiste, 
dénudé d‟intérêt. En quelque sorte, lorsque l‟on fait un don, il y aurait toujours un intérêt et 
donc un contre-don effectué sous des formes les plus diverses. Le don est alors assimilé à une 
forme d‟échange basé sur une exigence tacite de réciprocité. C‟est la réciprocité qui est sous-
entendue par l‟idée de « contre-don » : cela peut inclure la satisfaction personnelle d‟avoir 
donné, la gratitude, le renforcement de liens, ou encore se donner «bonne conscience». Cette 
vision est alors assez réductrice de l‟acte de donner, puisqu‟accomplie par intérêt et jamais par 
altruisme. Et malgré le sens premier de donner auquel on pense, on observe de nombreuses 
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expressions qui sous-entendent le contre-don, par exemple « c‟est donnant-donnant » ou « il 
faut donner pour recevoir ». 
Sans vouloir diminuer la portée du don du sang, il est intéressant de comprendre ce qui motive 
une personne à donner son sang. Selon un sondage effectué en Suisse en 2004, à la question 
« pour quelle raison donnez-vous votre sang », plus de 75% des personnes interrogées ont 
répondu « parce qu‟un jour, je pourrais en avoir besoin ». On est donc bien dans la logique du 
contre-don, ou plutôt contre-don « anticipé ». Ceci convient au principe de solidarité, aider les 
autres et être aidé en cas de besoin. Bien-entendu, parmi les réponses des donneurs, il y a 
aussi des réponses de type : « Pour sauver des vies » ou « Parce qu‟un proche a été 
transfusé ». Celles-ci peuvent être considérées comme étant davantage altruistes. 
Dans le monde de la transfusion, on oppose souvent « don-gratuit » (céder) à « don-
rémunéré » (échanger). Un don devrait être forcément gratuit, selon son sens premier ; et donc 
un don rémunéré est en quelque sorte un oxymore. On devrait parler plutôt de vente de sang 
dans ce dernier cas. Peut-être est-il plus acceptable « éthiquement », dans nos sociétés, de 
parler de don rémunéré plutôt que de vente de sang. Par la suite, quand il sera mentionné don 
rémunéré, il sera sous-entendu vente de sang comme il est d‟usage en transfusion. 
Afin de rendre hommage aux donneurs qui, par leur geste, permettent de sauver de 
nombreuses vies, nous nous permettrons de citer Khalil Gibran. Dans le contexte du don du 
sang, on peut détourner - avec une petite pointe d‟humour - le sens premier de sa phrase avec 
une interprétation au sens propre qui n‟était probablement pas l‟idée de l‟auteur : « Vous ne 
donnez que peu lorsque vous donner vos biens, c‟est lorsque vous donnez de vous-même que 
vous donnez réellement. » 
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L’éthique 
On parle souvent de problèmes et enjeux éthiques. Selon Wikipédia : l‟éthique (du grec 
êthikon, « la science morale ») est une discipline philosophique pratique (action) et normative 
(règles) dans un milieu naturel et humain. Elle se donne pour but d'indiquer comment les êtres 
humains doivent se comporter, agir et être, entre eux et envers ce qui les entoure. La morale et 
l‟éthique sont donc relativement proches comme termes et le langage courant les emploie 
souvent comme synonymes : cependant en voici les principale différences ; la morale a 
souvent une connotation religieuse, se porte sur le bien et le mal et impose des obligations de 
l‟extérieur. L‟éthique est plutôt de nature laïque, se porte sur le positif et le négatif et nous fait 
réfléchir, nous responsabilise. L‟éthique délimite des principes qui permettent de faire des 
choix libres et responsables face à une situation dans un cadre donné. En fonction de la 
culture, de la société, du temps, de l‟évolution des mœurs, les principes éthiques peuvent 
varier. Avec l‟essor des nouvelles technologies et de la science, les limites étant repoussées 
sans cesse, les principes éthiques doivent s‟adapter face à des problématiques nouvelles. C‟est 
donc pour cela que bien souvent l‟éthique se retrouve à l‟interface entre progrès médicaux, 
nécessité économique et protection de la dignité humaine. En Europe occidentale, les 
principes éthiques du don de sang reposent généralement sur quatre piliers : 
Le volontariat : le don du sang doit relever de la seule volonté du donneur, et ne doit en 
aucun cas être lié à une quelconque obligation. 
La gratuité : le don du sang ne doit pas donner droit à des contreparties financières et les 
produits sanguins labiles ne doivent pas faire l‟objet d‟un commerce. 
L’anonymat : l‟identité du donneur ne doit pas être connue du receveur et vice-versa. 
La responsabilité : le donneur s‟engage à ne dissimuler aucun élément susceptible de nuire à 
la santé du receveur lors de l‟entretien médical. 
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L‟organisation mondiale de la santé (OMS), la Croix-Rouge ainsi que d‟autres organisations 
tentent de faire adopter ces principes éthiques dans un maximum de pays à travers le monde. 
 
Les motivations 
Le nombre de produits sanguins disponibles pour les hôpitaux est directement dépendant de la 
volonté des donneurs de sang. On peut se demander quelle est la motivation de ces personnes. 
En effet, il n‟y a pas de bénéfice direct, c‟est donc un comportement qui peut être considéré 
comme altruiste et pro social, relativement rare dans notre société de consommation moderne 
individualiste. Plusieurs théories tentent d‟expliquer un tel comportement qui fait passer le 
bénéfice des autres avant le sien. 
Pour tenter d‟expliquer cette forte motivation à donner son sang, revenons brièvement à 
l‟histoire de la transfusion. La première transfusion « moderne » réussie fut effectuée en 1818. 
Avec l‟amélioration des techniques et de meilleures connaissances, c‟est dans les années 
1930, plus d‟un siècle plus tard, que les premiers services de transfusion furent mis en place. 
L‟essor de la transfusion eut lieu pendant la seconde guerre mondiale. Durant cette période, le 
principe de solidarité sera mis en avant. En effet, en donnant leur sang, les citoyens pouvaient 
« soutenir » l‟effort de guerre et « sauver » indirectement la vie de soldats blessés sur les 
champs de bataille. De ce fait, dès le début de la transfusion moderne, le don du sang (sous-
entendu sans contrepartie) fut perçu par la population comme un acte positif, voire même un 
acte de résistance et de nationalisme. L‟urgence de la guerre a probablement permis à la 
transfusion d‟échapper non seulement aux réticences de certains médecins (la transfusion 
comporte des effets indésirables et des risques) mais aussi à la méfiance de la population vis-
à-vis d‟une technique nouvelle. A la fin de la guerre et, en conséquence des avancées de la 
chirurgie - grande consommatrice de sang -, il fallut de nouveaux moyens pour motiver les 
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gens à donner leur sang afin de subvenir aux besoins des hôpitaux. Dès le début des années 
50, aux Etats-Unis notamment, le principe de don rémunéré s‟imposa tandis qu‟en Europe, 
d‟une manière générale, c‟est le don gratuit qui fut valorisé en tant qu‟acte de solidarité 
citoyen, rassembleur et fédérateur, symbole de l‟unité d‟un peuple en bonne santé. 
Aujourd‟hui encore le don du sang continue de bénéficier d‟une image très positive, et cela 
malgré les scandales des affaires du sang contaminé des années 80. Actuellement, dans notre 
société, l‟action de donner son sang semble encore et toujours perçue comme un acte 
considéré « moralement » bon par essence. 
 
L’image du don du sang 
L‟image positive du don du sang, action solidaire envers son prochain ou signe de bonne 
santé, permet le postulat collectif suivant dans notre société : « il est normal de donner son 
sang ». Malencontreusement, l‟exclusion d‟une personne pour une raison ou une autre fait que 
cette dernière n‟est plus dans la « normalité » et sous-entendrait même qu‟elle serait malade. 
De ce fait, par l‟exclusion du don, c‟est comme si le donneur potentiel ne faisait plus partie du 
système de solidarité, comme une « mise au ban » de la société. Les critères d‟exclusion sont 
devenus, au fil des ans, de plus en plus drastiques et de plus en plus nombreux - afin de 
garantir la sécurité des produits sanguins -. Cette dérive sécuritaire a eu pour conséquence que 
les personnes exclues sont devenues de plus en plus nombreuses. A titre indicatif, au service 
de transfusion de Lausanne, près du tiers des personnes qui se présentent pour la première fois 
sont exclues du don. L‟exclusion est parfois très mal vécue, et les services de transfusion se 
retrouvent dans une position délicate ; en effet, ils doivent promouvoir le don du sang, mais 
en même temps refuser de nombreuses personnes. Le message contradictoire qui peut en 
ressortir est « donner votre sang, mais pas vous ! ». En voici quelques exemples : 
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 Certaines personnes âgées (mais que veut dire l‟âge ?), habituées à donner leur sang 
depuis de nombreuses années, se voient refusées sous prétexte que le don du sang 
pourrait représenter un danger pour leur santé. Elles se sentent alors rejetées. 
 Les personnes ayant été transfusées ne peuvent plus donner leur sang depuis la fin 
des années 90 car le prion (responsable de la maladie de Creutzfeldt-Jacob) pourrait être 
transmis du donneur au receveur qui à son tour, s‟il donne son sang, propagerait la 
maladie. De même, la chaîne de transmission des maladies inconnues, par le sang, serait 
maintenue. De nombreuses personnes ayant été transfusées (11% de la population des 
donneurs de sang du Canton de Vaud) donnaient leur sang depuis des années, 
représentant ainsi une opportunité de rendre le geste que d‟autres personnes avaient eues 
pour elles. C‟est pourquoi cette mesure de précaution fut particulièrement mal comprise 
et mal acceptée par les personnes concernées. 
 Les hommes ayant des relations sexuelles avec des hommes sont également exclus 
du don
1
 en raison de la prévalence élevée du VIH dans ce groupe. Ils ressentent 
l‟exclusion du don du sang comme particulièrement discriminatoire et injuste, compte 
tenu de leur volonté de faire partie de la « normalité », d‟une recherche de 
reconnaissance sociale et de solidarité associée au don du sang. De plus, cela renvoie 
directement au lien simplificateur, encore souvent fait entre SIDA et homosexuels, dont 
ces derniers tentent de se défaire. 
 
Rémunération 
Dans la plupart des pays européens, le don du sang fait partie des mœurs et jouit d‟une image 
très positive. Ce n‟est pas le cas dans les pays dans lesquels le don du sang a été mis en place 
                                                 
1
 Les mots « Etre exclu du don » portent toute l’ambigüité de la réalité du quotidien des médecins du don. 
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après la seconde guerre mondiale. La rémunération peut être un moyen incitatif, bien 
paradoxal dans les pays pauvres. La rémunération du sang pose aussi des problèmes éthiques 
car une personne dans le besoin peut « mentir » et ne pas répondre correctement au 
questionnaire d‟évaluation et mettre sa propre santé en danger, par exemple en donnant son 
sang plus souvent que les prescriptions ne l‟autorisent. Bien souvent également, dans les 
systèmes de santé qui poussent les individus à donner pour des raisons financières, ces 
donneurs risquent eux-mêmes de ne pas avoir accès aux transfusions thérapeutiques en cas de 
nécessité, par manque de moyens ou par absence d‟assurance sociale. En quelque sorte, on 
prélèverait le sang des plus pauvres au profit des plus riches. C‟est entre autre pour ces raisons 
que l‟OMS a décidé de s‟engager en faveur du don « véritable » du sang, sans rémunération. 
 
Don volontaire et gratuit 
Selon l‟article 21 de la directive du conseil de l‟Europe 2002/98/CE du 27 janvier 2003, 
également ratifiée par la Suisse, « Les États membres prennent les mesures nécessaires pour 
encourager les dons volontaires et non rémunérés en vue de garantir que, dans toute la mesure 
du possible, le sang et les composants sanguins proviennent de ces dons». Les pays européens 
sont « encouragés » à promouvoir « dans la mesure du possible » les dons volontaires et non 
rémunérés. Cette directive non contraignante laisse beaucoup de liberté à chaque état. Dans la 
plupart des pays, le don est « non rémunéré » alors que dans certain pays comme la Hongrie 
ou l‟Autriche, les deux systèmes, rémunéré et non rémunéré se côtoient. Enfin, dans des pays 
comme la Lituanie, le don est rémunéré. 
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Indemnité, reconnaissance ou rémunération ? 
Bien que le don volontaire et non rémunéré soit reconnu dans la plupart des états européens, 
son interprétation varie d‟un pays à l‟autre. L‟absence de rémunération n‟exclut pas que les 
donneurs puissent recevoir une « indemnisation » qui doit, en théorie, se limiter à compenser 
les dépenses occasionnées pour effectuer le don. En plus d‟une petite collation, dans la plupart 
des pays, il est d‟usage courant d‟offrir un petit cadeau pour remercier le donneur allant du 
porte-clés aux billets de concert… Cependant, l‟indemnisation ou un petit cadeau de 
remerciement ne doivent en aucun cas être la source de motivation des donneurs. Dans 
certains pays comme la Suisse, des cérémonies avec remise de broches, diplômes ou 
médailles sont organisées pour remercier les personnes qui ont effectué un certain nombre de 
dons. Seuls cinq pays en Europe appliquent strictement le principe de volontariat et non 
rémunération et n‟offrent rien pour remercier ou inciter les donneurs à revenir. 
La France fut l‟un des premiers pays à inscrire le principe de gratuité du don du sang dans la 
loi, en 1952. En Allemagne, la loi sur la transfusion interdisant aussi la rémunération (mais 
autorisant le versement d‟une indemnité) a été adoptée en 1998. En Allemagne, deux 
systèmes de collecte se côtoient, l‟un public organisé par la Croix-Rouge et l‟autre privé. 
Contrairement aux collectes organisées par la Croix-Rouge, les centres de collecte privés 
prévoient une « indemnisation » forfaitaire d‟une vingtaine d‟euros pour couvrir les frais de 
déplacement ou de dérangement pour un don de sang complet, l‟indemnisation ne devant pas 
constituer la source de motivation. Cependant, un industriel du fractionnement comme 
Heama, lié à l‟industrie pharmaceutique, a développé un site internet bilingue, en allemand et 
en polonais (http://www.haema.de/?L=1), ce qui incite ces derniers où le niveau de vie est 
inférieur à venir donner leur sang en Allemagne. Comme le don de sang n‟est pas rémunéré, 
ni « indemnisé » en Pologne, cela peux créer des problèmes d‟approvisionnement dans les 
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régions frontalières. L‟Allemagne tolère cette pratique qui pourtant est discutable. Tout est 
donc une question d‟interprétation. Si la plupart des citoyens européens soutiennent le don 
« bénévole », la perception du bénévolat et de ce qui est éthiquement acceptable varie d‟un 
pays à l‟autre, la frontière entre rémunération, reconnaissance ou indemnité n‟est pas toujours 
aussi claire qu‟elle n‟y paraît au premier abord. Dans notre société de consommation, le don 
du sang fait partie des dernières actions altruistes avec un principe de solidarité qui perdure. 
Pourtant, dans cette société dites de « services », il est considéré comme normal d‟être payé 
pour un service rendu. Dès lors, pourquoi ne pas appliquer ce principe au don du sang ? Cela 
pourrait se révéler efficace pour inciter plus de personnes à donner leur sang. Néanmoins, il 
ne faut pas négliger la symbolique du sang, le fait de savoir qu‟un don de sang permet de 
sauver des vies et cela est jusqu'à présent une des sources de motivation suffisante pour 
justifier la gratuité de l‟acte dans une perspective de solidarité. Au delà de la valeur de 
l‟action, donner son sang est aussi une manière unique de relier les citoyens les uns aux 
autres. La rémunération pourrait changer la perception et la symbolique forte de l‟acte, le sang 
deviendrait un bien de consommation comme un autre. 
 
Le paradoxe du plasma 
Par le don de sang, on sous-entend ce qu‟on appelle un don de sang complet, soit le sang 
comprenant tous ses éléments, c‟est à dire, le plasma, les globules rouges, les globules blancs 
et les plaquettes. Cependant, il existe également d‟autres types de don de sang, à savoir le don 
de plaquettes ou de plasma, qui sont prélevés par une technique que l‟on appelle « aphérèse ». 
Grâce à cette technique, on peut prélever un élément particulier du sang, et restituer le reste au 
donneur. Si le principe de don du sang « complet » bénévole est généralement le plus répandu 
en Europe, le don de plaquettes dans une moindre mesure, mais surtout le « don » de plasma, 
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sont rémunérés dans plusieurs pays. Le plasma sert à la fabrication de médicaments, comme 
des facteurs de coagulation ou des immunoglobulines. La demande en médicaments à partir 
de plasma augmentant, l‟industrie pharmaceutique s‟intéresse beaucoup à ce marché très 
lucratif. Le prix des médicaments à base de plasma humain augmente d‟années en années. 
Dans un nombre non négligeable de pays, le don de sang complet bénévole coexiste avec le 
« don » de plasma rémunéré dans des centres de plasmaphérèse, bien souvent des succursales 
de compagnies pharmaceutiques. 
Comme le plasma sert à la fabrication de médicaments, la symbolique autour de cet acte n‟est 
pas la même que celui du sang complet. De ce fait, il est mieux accepté que le plasma soit 
rémunéré contrairement au sang complet. La vente du plasma relève d‟ailleurs d‟un autre 
cadre législatif que le don de sang. Dans ce contexte, la parole est donnée à un industriel du 
plasma dans la section suivante 
 
Visions d’un industriel du fractionnement du plasma 
Le Dr Ruedi E. Wäger, scientifique ayant dirigé des grandes entreprises de fractionnement de 
plasma, dans un chapitre récemment rédigé et consacré à l‟industrie du plasma apporte un 
éclairage personnel sur cette éthique commerciale de la vente du sang
2
. 
Il note que « l'augmentation explosive de la demande en albumine, en immunoglobulines et 
en Facteur VIII a fait apparaître que le plasma, issu des dons de sang collectés par les services 
de transfusion, ne peut plus couvrir les besoins en produits dérivés et que, de ce fait, il n'est 
pas surprenant que l‟industrie de fractionnement de plasma se soit intéressée à des solutions 
alternatives passant par le développement de machines automatisées pour prélever 
                                                 
2
 Ruedi E. Wäger : L’industrie mondiale du plasma sanguin. Dans : Sang : arts, sciences et vies (Ph. 
Schneider, J.-D. Tissot, M. Benzoni et O. Ribes, éditeurs). Editions Favre, Lausanne, Paris, sous presse. 
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sélectivement le plasma en restituant les autres composants du sang aux donneurs. Ainsi, des 
entrepreneurs et des investisseurs ont construit des centres de collecte de plasma aux Etats-
Unis, permettant à la plupart des gros producteurs d‟être pratiquement indépendants dans leur 
approvisionnement de plasma ». C‟est dans ce contexte que les donneurs de plasma sont 
rémunérés et cette situation est justifiée par une personnalité comme Wäger qui indique 
« Personnellement, je pense qu‟il est plus éthique d'indemniser des donneurs de plasma 
soigneusement sélectionnés et fiables que de priver les patients de traitement par des produits 
dérivés de plasma ». Le débat est ouvert, le système est culpabilisé. Nous sommes défenseurs 
d‟une éthique du bénévolat, mis face à nos responsabilités. Alors, Wäger ajoute « S‟il est vrai 
que les donneurs américains sont rémunérés pour leurs dons de plasma (entre 20 et 30 dollars 
par don en fonction du besoin en plasma, il ne faut pas oublier que ces donneurs doivent se 
déplacer jusqu'au centre de collecte et que la séance de plasmaphérèse (y compris le temps 
d'attente et l'examen du donneur) prend jusqu'à deux heures ». Dans son argumentaire, Wäger 
affirme ; « Lors de centaines d'entretiens avec des donneurs rémunérés aux Etats-Unis, j'ai 
appris que leur principale motivation est d‟aider les patients qui ont besoin de produits dérivés 
de plasma. Elle n'est pas moins valable que celle des donneurs de sang bénévoles. Par ailleurs, 
je constate que dans de nombreux pays (France, Allemagne, Japon, etc.), les donneurs de sang 
et de plasma du secteur non commercial reçoivent fréquemment des compensations ou des 
incitations au don » et de poursuivre « Le débat sur la valeur et l'éthique respectives des dons 
de sang entier ou de plasma sur une base bénévole non rémunérée et des dons de plasma 
rémunérés représente le vestige d'une sorte de guerre de religion, qui est loin de la réalité. 
Comment le secteur à but non lucratif pourrait-il remplacer les 20 millions de litres de plasma 
qui lui manquent pour satisfaire les besoins des patients en produits dérivés de plasma, alors 
que ce secteur est juste en mesure de couvrir les besoins locaux/nationaux en globules rouges, 
plaquettes et plasma frais congelé par les services de transfusion sanguine ? Pourquoi les 
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patients, qui souffrent de maladies mettant leur vie en danger et qui ont besoin de produits 
contenant des protéines plasmatiques, ne seraient-ils pas traités de manière adéquate, sous 
prétexte que certains estiment que les dons de plasma rémunérés ne sont pas éthiques ? Les 
secteurs commerciaux et non commerciaux ont des logiques et des justifications fortes à 
continuer de servir la communauté et les patients, malgré des approches et des philosophies 
différentes, en étant fiers de leur tâche, en se concentrant sur leurs points forts et en respectant 
les principes éthiques établis ». 
Le don dirigé, une alternative ou un interdit 
Le don dirigé est mal aimé dans nos pays ; il est considéré comme peu sécuritaire, comme 
trahissant l‟éthique établie par les pays occidentaux, comme un tabou, comme une dérive des 
pays pauvres inaptes à développer un système de transfusion à l‟européenne ou à 
l‟américaine. Il force des individus ne désirant pas donner pour un proche à dévoiler leurs 
secrets, à se mettre à nu au service d‟un frère, d‟un ami, d‟un père. Mais, à l‟image du 
commerce du sang, la transfusion dirigée, ou intrafamiliale est-elle un interdit définitif ? 
La parole est donnée à Jean-Pierre Allain et à Dora Mbanya. Dans leur chapitre intitulé « La 
Transfusion en Afrique
3), ces auteurs apportent un éclairage qu‟il ne faut pas négliger, 
lorsque, de notre hauteur d‟européens civilisés, nous examinons la transfusion sanguine dans 
une vision de mondialisation égoïste. 
 
Le sang des pays pauvres 
Allain et Mbanya rappellent que dans nos pays, les produits sanguins sont transfusés le plus 
souvent à des patients présentant un déficit de production (d‟origine médicamenteuse 
                                                 
3
 Jean-Pierre Allain & Dora Mbanya : La transfusion en Afrique. Dans : Sang : arts, sciences et vies (Ph. 
Schneider, J.-D. Tissot, M. Benzoni et O. Ribes, éditeurs). Editions Favre, Lausanne, Paris, sous presse. 
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thérapeutique, suite à des transplantations d‟organes, de moelle ou de chimiothérapie pour 
cancer, ou lié à l‟âge des receveurs – ayant soit plus de 70 ans ou moins de 3 ans) et que les 
transfusions d‟urgence représentent une part moins importante de l‟acte transfusionnel. En 
Afrique, la transfusion reste une thérapeutique d‟urgence pour les anémies aiguës (paludisme 
chez les enfants de 0 à 5 ans, hémorragies aigues péri- ou post-natales, patients subissant une 
intervention chirurgicale). Les cas de transfusion « médicale » sont une minorité, même en 
comptant les anémies congénitales comme la drépanocytose ou la thalassémie majeure. Dans 
toutes ces indications, le sang total (qui est quasi introuvable dans les pays développés) est le 
produit sanguin de base. En Europe, la « publicité » pour le don de sang dit que donner son 
sang sauve des vies. En réalité, ce n‟est pas toujours le cas, les transfusions sont prescrites 
pour le confort du malade, pour des anémies modérées liées à des interventions ou pour 
maintenir en vie des patients. En Afrique, c‟est l‟inverse. Les dons de sang sauvent des vies. 
Les dons sont bénévoles et reposent en majeure partie sur les étudiants âgés de 16 à 19 ans, 
qui constituent 50 à 70% des donneurs de sang. Ceux-ci sont réputés sûrs parce que l‟OMS et 
les instances transfusionnelles internationales ont estimé que le risque d'infection était 
moindre avec seul le sang de donneurs volontaires non-rémunérés. Néanmoins, la pénurie de 
sang est chronique. Dans beaucoup d‟hôpitaux, la règle est : « pas de don familial, pas de 
transfusion ». Malgré les recommandations de toutes les organisations internationales, les 
donneurs familiaux continuent de fournir la majorité des dons de sang, même si les donneurs 
familiaux sont dangereux, car on ne peut les distinguer des donneurs « payés » par les familles 
incapables de fournir un donneur. Dans leur analyse, Allain et Mbanya examinent en détail les 
données épidémiologiques afin d‟évaluer scientifiquement si, selon le credo officiel et 
occidental, les donneurs familiaux sont plus dangereux et doivent être écartés du don de sang. 
De leurs travaux, une conclusion essentielle s‟impose : seule la répétition du don de sang 
procure un avantage en termes de sécurité, pas le type de donneur. Toujours selon Allain 
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et Mbanya, si les donneurs familiaux étaient intégrés dans les collectes de sang, moins de 
malades mourraient par manque de sang et la sécurité transfusionnelle n‟en serait pas 
amoindrie. Ces observations sont importantes pour dégager objectivement une éthique globale 
du don de sang. 
 
Le sang des Suisses 
Le sang des Suisses a été vendu et a été versé durant des siècles. Des régiments suisses se 
battaient parfois entre eux, l‟un défendant les intérêts d‟un roi, d‟un prince ou d‟un Pape. 
Manière d‟affaiblir la terre et les fermiers en les privant de bras, en les écrasant de labeur, en 
les privant des âmes de la révolte. Le sang des Suisses était exploité déjà par les propriétaires 
terriens, les nobles pour maintenir leur pouvoir et/ou leurs droits féodaux. Cette exploitation 
du sang a perduré, sous d‟autres formes. Les anciens qui ont connu le Laboratoire Central de 
la Croix-Rouge suisse (ZLB) parlent encore de collectes massives de sang, avec comme 
objectif principal l‟accumulation du plasma pour la préparation de produits sanguins dérivés 
stables, notamment pour produire des immunoglobulines intraveineuses. Ils se souviennent, 
sans dire précisément s‟il s‟agit d‟une légende ou de la réalité, que l‟excès de globules rouges 
collecté était déversé dans l‟Aare, rivière bien connue des bernois. Légende ou réalité ? 
Toujours est-il que l‟excès de globules rouges a bel est bien été une réalité et qu‟il a fallu 
l‟exploiter. Des milliers de concentrés érythrocytaires ont été vendus hors de Suisse. Des 
accords ont été passé entre le ZLB et le New York Blood Center d‟une part, et avec le 
gouvernement grec d‟autre part. Le risque de transmission de prions, les restructurations 
internes, puis la vente du ZLB, par la Croix-Rouge suisse, à des industriels du fractionnement 
du plasma ont totalement modifié la situation au XXI
ème
 siècle. Des concentrés érythrocytaires 
sont toujours vendus en Grèce dans le cadre d‟une collaboration entre le Service suisse de 
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transfusion sanguine (Transfusion CRS Suisse) et le gouvernement Grec 
(http://www.blutspende.ch/fr/qui-sommes-nous/organisation/organisation-
nationale/programme-dexportation-vers-la-grece/), en particulier pour soutenir les 
programmes de prise en charge de patients thalassémiques. 
Vente, commerce, don bénévole, exportation…. ; tous ces mots sont porteurs de sens très 
contradictoires. Cette situation pour le moins paradoxale a fait l‟objet de nombreux débats et 
questionnements dans la presse helvétique ces dernières années. La question de fond reste 
entière ; commerce de sang ou exploitation optimale des ressources ? La transfusion sanguine, 
en Suisse dépend de la Croix-Rouge suisse dans une organisation appelée en français 
« Transfusion CRS Suisse » et « Blutspende SRK Schweiz » en allemand, ce qui se traduit en 
français par « Don du sang CRS Suisse ». Premier paradoxe, le champ linguistique diffère et 
couvre des notions différentes. La transfusion est une activité clinique globale, qui a ses règles 
économiques, son marché, ses normes. Le don de sang représente un seul de ces aspects. Le 
don du sang en Suisse est bénévole et volontaire. La transfusion sanguine est payante. Comme 
le répètent à l‟envi les responsables hospitaliers et les assureurs, le sang est cher, d‟autant 
qu‟il s‟agit d‟une matière périssable et rare. Second paradoxe, les hôpitaux ont des budgets 
importants pour acheter ce sang donné, ce sang gratuit, ce sang fourni bénévolement. 
Troisième paradoxe, voire scandale pour les médias, c‟est la vente aux industries de 
fractionnement du plasma dérivé du sang complet ou collecté par aphérèse chez ces donneurs 
bénévoles. Scandale pour certains journalistes, qui ont dénoncé, dans une émission de la 
Télévision Suisse Romande, en 2007, le fait que du plasma collecté chez des bénévoles était 
vendu par les services suisses de transfusion sans que les donneurs puissent décider, en toute 
connaissance de cause, du devenir de leur don. En effet, l‟information fournie aux donneurs 
était insuffisante, laconique souvent, inexistante parfois. Les donneurs ne pouvaient ni 
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comprendre les enjeux financiers liés à leurs dons ni les implications éthiques y relatives. Le 
principe du consentement éclairé était clairement bafoué. 
Commerce du sang ; scandale du commerce du sang suisse ! En Suisse ce n‟est pas le sang ou 
ses dérivés, comme les plaquettes ou le plasma destiné à la transfusion, qui sont vendus ; c‟est 
le travail et les services nécessaires à sa préparation et à son conditionnement qui sont l‟objet 
d‟un commerce répondant aux règles économiques du marché de la santé. Mais le plasma 
destiné au fractionnement, dans ce contexte, pose un problème. En effet, sa vente en tant que 
matière première nécessaire à la fabrication de médicaments trahit, pervertit la notion de 
gratuité du don. Même si les revenus dégagés de cette vente permettent de diminuer les 
charges relatives au fonctionnement des systèmes de prélèvement, de conditionnement, de 
sécurité, d‟analyses, de stockage, la vente du plasma représente un vrai commerce qui a ses 
règles et éventuellement son éthique propre. 
En Suisse, les produits sanguins sont, sur le plan législatif, considérés comme des 
médicaments (Loi fédérale sur les médicaments et les dispositifs médicaux : 
http://www.admin.ch/ch/f/rs/8/812.21.fr.pdf). Il est dès lors peu étonnant que les industriels 
puissent considérer le plasma comme une matière première, qui a un prix et un marché. Les 
exigences des « GMPs » qui sont appliquées à la lettre pour la préparation du plasma, sont 
assez éloignées des considérations éthiques biomédicales et humanistes qui font les valeurs 
implicites de la médecine du don. Ces mondes divergents doivent se trouver, se rencontrer, 
éventuellement se confronter, afin d‟éviter une schizophrénie du raisonnement et de la pensée 
qui nous guette et qui place les donneurs en otage de nos errances décisionnelles. En somme, 
en Suisse, ce n‟est pas le donneur qui est rémunéré ; ce sont les services de transfusion, qui, 
par la vente du plasma, « corrompent » le sens du don, dans un souci de restreindre les coûts 
globaux. L‟éthique commerciale domine l‟éthique biomédicale. Les deux ont leur valeur et 
leur sens. Ceci dit, le message délivré aux différents partenaires de la chaîne transfusionnelle 
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est confus ; il nécessite urgemment un effort de clarification et d‟information permettant aux 
donneurs de faire leur choix de manière éclairée. 
 
Vers une psychothérapie de la médecine du don ? 
Comme le dit si bien le philosophe allemand Andris Breitling « Il existe des actes de 
générosité qui échappent à toute logique économique ». Le don de sang est comme un acte 
d‟amour, un geste altruiste vers son prochain. La générosité est une vertu sociale par laquelle 
on gagne son honneur. Et si, comme le pense Breitling « Le don du sang était un exemple de 
surabondance, voire de débordement de bonté ». Même si le don du sang est bénévole et 
gratuit, même si le donneur ne semble percevoir aucun bénéfice ou avantage matériel, il 
pourrait être malgré tout récompensé en se procurant une bonne conscience, et comme le dit 
Friedrich Nietzsche « Une bonne conscience permet un sommeil de qualité ». A la lecture de 
ces lignes, comment se positionner, quelle liberté prendre, comment reparler du sens du don ? 
L‟éthique doit nous conduire dans nos réflexions, elle n‟est en aucun cas la solution. 
Revendiquer l‟éthique est la placer dans un champ qui emprisonne la pensée. Utiliser les 
principes éthiques permet de penser la liberté, y compris dans les valeurs du don de sang. 
Ouvrons donc la porte de la psychanalyse de café du commerce : et si la « sexualité » - dans 
sa représentation symbolique - était une piste de réflexion nous renvoyant à – ou nous 
éclairant sur – nos convictions souvent dogmatiques touchant le don bénévole ou la 
rémunération du sang collecté ? 
Eléments de réflexion : 
 La vie est donnée, transmise par l’acte sexuel. 
 La vie est donnée, portée par le sang, transmise par le sang. La vie est offerte par 
l’acte de donner son sang. 
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 La mort est portée par le sexe – contaminé –. 
 La mort est portée par le sang – contaminé –. 
 Donner la vie, par le don du sang, est de fait une représentation symbolique de 
l’acte sexuel, porteur de vie et de mort. 
 L’acte sexuel est acte d’amour : il est libre, il est partage. 
 L’acte sexuel tarifé résulte d’une transaction commerciale ; il est considéré 
comme impur et est souvent tabou dans nos sociétés – prostitution –. 
Perspectives :  
 La vente du sang pourrait représenter, tout au moins sur le plan symbolique et 
dans l’inconscient collectif, un acte sexuel tarifé et de ce fait, être l’expression 
d’une relation impure, d’une relation porteuse d’interdit, d’une relation dénuée de 
la notion d’amour du prochain. 
 Le don dirigé porte en lui une image incestueuse, est un symbole du mariage 
arrangé – forcé –, est une de perte de liberté. 
 L’exclusion d’un donneur est l’expression cachée d’une impuissance sexuelle 
imposée au donneur, est une représentation allégorique de castration. 
 La vente du plasma aux industriels, ou l’exportation du sang collecté « en trop » 
(ou désigné plus diplomatiquement comme « réserve nationale » en Suisse), 
raisonnent dans notre inconscient comme une sorte de proxénétisme, comme une 
parabole moderne et détestable de la traite des blanches. 
Sexe et sang ; un binôme indissociable comme la vie et la mort. L‟argent comme vecteur de 
contrôle, de puissance. La transfusion sanguine est au carrefour des valeurs humaines. Ce sont 
ces valeurs qui nous confrontent dans nos réalités et rendent la réflexion si complexe. 
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Quoiqu‟il en soit, ne mettons pas l‟éthique du don bénévole en otage d‟une psychologie bon 
marché, par un examen, soit trop superficiel, soit inversement par une analyse exagérément 
poussée des données et des symboles de notre réalité de médecins impliqués dans la chaîne 
transfusionnelle. Les organisations transfusionnelles doivent expliquer, clarifier, définir des 
positions explicites, afin que les donneurs puissent décider librement, en conscience. 
Expliquons, clarifions, communiquons ; soyons vecteurs de la liberté du don ! Nous devons 
dépasser notre vision habituelle et simplificatrice des choses. 
Ceci dit et pour paraphraser Breitling « Les donneurs ne devraient pas trop s’attarder sur 
les symboles mais simplement faire ce qui est juste. Donner son sang est vraiment facile. 
Il est sans doute très intéressant de penser aux implications éthiques et philosophiques 
d’un tel geste mais, finalement, on devrait simplement le faire ». Et nous, dans nos 
organismes de transfusion, soyons honnêtes, transparents et au service de cette chaîne 
d‟humanisme qui lie le donneur et le receveur. 
 
Conclusions 
Ces quelques paragraphes ont été l‟opportunité de pouvoir partager des préoccupations 
et des réflexions de personnes travaillant dans le domaine de la transfusion sanguine. Ces 
visions sont biaisées, volontairement peut-être. Des éclairages arbitraires ont été choisis. La 
sécurité transfusionnelle, le rationnement des ressources, l‟adéquation avec les coûts de la 
santé et une vie humaine sauvée renvoient directement à des choix existentiels de société, et 
comme on peut le voir, ces questions dépassent largement le cadre de la transfusion. 
Pour le moment, en Suisse et malgré les perversions énoncées plus haut, le système de don 
non rémunéré perdure grâce à de nombreuses personnes qui participent à la solidarité. En tant 
que trait d‟union entre les donneurs et les receveurs, les services de transfusion ont un 
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engagement tacite et une responsabilité afin de fournir des produits sanguins sûrs et 
qu’il en soit fait bon usage. Il ne faut pas condamner d‟autres approches, il faut les 
comprendre, les placer dans leur contexte et la réalité qui diffère si souvent d‟un endroit à 
l‟autre, d‟une culture à l‟autre. 
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Main results  
 
Counting Methods  
A counting method was developed using flow cytometry. The size of erythrocyte-derived 
microparticles (EMPs) and heaps of EMPs were defined using beads of 1 µm to set up the 
gate of EMPs. A precise number of fluorescent “trucount” beads allows obtaining a 
concentration of EMPs per µl. As it appears that EMPs tend to aggregate and form heaps, it is 
considered that this method is semi-quantitative. With double labeling and size it is possible 
to isolate MPs from background noise. In erythrocyte concentrates (EC) as well as in their 
supernatant, an increase in number of MPs according to storage time has been observed. 
Analysing directly in the EC, 3300 ± 1100 EMPs/ µl were counted after 5 days of storage. 
This number slowly increases until around 25 days of storage. After 35 days of storage, the 
increase is more pronounced and sharp and variability among samples goes wideer. After 42 
days of storage corresponding to the usual shelf life of EC, the count reaches 35‟400 ± 14‟000 
EMPs/ µl. This number almost double between 42 and 50 days of storage (Fig 1). This is most 
likely due to physicochemical changes that affect erythrocyte viability. As a result, the release 
of EMPs is amplified.  
Figure 1: Count of microparticles in seven erythrocyte concentrates during storage 
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Surface Antigens 
More than the half of RBC transmembrane proteins carries various group antigens.  Those 
proteins play crucial role for the immune system and allow recognition of “self” antigens 
from “non-self” ones.  Those antigens were shown to be present on EMPs too.  
By proteomic study (1DE-LCMS/MS), Rh peptides were identified on EMPs. Rh group 
antigens also play a role in membrane stabilization suggesting that they may take part to the 
process of EMPs formation and release.  
By flow cytometry, several blood group antigens were shown to be present on EMPs. Those 
groups of importance for transfusion are RH1, RH2, RH3, RH4, RH5, FY1, FY2, JK1, JK2 
and KEL 1 (Fig 2). 
Figure 2: Flow cytometry results showing the presence of various blood group antigens on 
EMPs.  
 
For each antigen, specific 
antibody was employed 
and as negative control an 
antibody against another 
antigen was employed. A 
line through the mean peak 
show labeled 
microparticles. In the 
histogram corresponding to 
the negative control the 
peak of microparticles 
appears on the left of the 
line, indicating non labeled 
events.        
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Erythrocyte-derived microparticle proteins  
In order to elucidate the roles of EMPs, analysis of their protein content by one dimensional 
gel electrophoresis (1D-GE) was performed. EMPs were directly solubilized in 1D-GE 
loading solutions such as Laemmli, containing SDS and reducer. Proteins were then separated 
by 1D-GE. The protein bands of interest were cut, and further digested by trypsin and 
identified by MALDI-TOF/TOF. The clear-cut advantage of this technique, compared to gel-
free approaches, is that to some extent 1D-GE is compatible with the analysis of hydrophobic 
proteins, due to the fact that EMPs contain more membrane proteins. Erythrocyte membrane 
and erythrocyte MP samples were first compared by 1D-GE (Fig 3). Both sample were 
obtained from a 42 days stored EC. The gel was stained with Coomasie blue for better 
compatibility with mass spectrometry. Slight differences of pattern were observed. A major 
difference was observed in the 25–35 kDa region; thus, in order to perform protein 
identification, bands of interest stained with Coomassie blue were excised and proteins were 
identified by MS (Fig 3). Western blot analysis allowed to thoroughly quantify the differences 
in specific protein content in both sample. Thus, by comparing erythrocyte membranes and 
EMPs, a clear reduction of actin and an accumulation of stomatin were observed on EMPs. 
The immunodetection of CD235a (glycophorin A) was similar in both gels (Fig3). Those 
results were well in line with previous report [86]. Stomatin is a membrane protein involved 
in regulation of monovalent cation transport through lipid membranes. Interestingly, stomatin 
(which has a structure similar to caveolin) is a major lipid-raft component of erythrocytes 
[87]. Precise reasons of stomatin enrichment in EMPs are not well known and are still subject 
of investigation, but may have a role in membrane microdomains modulation leading to 
membrane budding and EMPs release. The cell membrane plays a key role in the formation of 
EMPs. Indeed, following a stimulus, increase in intracellular calcium occurs and activates 
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proteases that cleave cytoskeleton proteins (actin and spectrin). Membrane is thus less rigid 
and can bud until formation of EMPs. 
 
Figure 3: Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE)of 
erythrocyte membranes and microparticles 
                                                                                                                                     
Both samples (A and B) were 
from a 42-day stored 
erythrocyte concentrate. The 
gel was stained with 
Coomassie blue (for better 
compatibility with MS). Inset 
shows enlargement of 
Coomassie blue-stained gel 
used for the preparation of the 
bands submitted to mass 
spectrometry analysis. 
Western blot analysis points 
out the variation of protein 
expression. Thus, by 
comparing erythrocyte 
membranes and 
microparticles, a clear 
reduction of actin and an 
accumulation of stomatin 
were observed on 
microparticles. The staining 
of CD235a (glycophorin A) 
was similar in both gels. 
 
 
1D-GE provided another level of information that is complementary to the MS/MS 
identification of proteins based on a few peptides: the molecular weight of the identified 
protein can indeed be deduced from its position on the gel, which can sometime provide some 
indications about protein processing. For example, in a slice of EMPs separated by 1DGE, 
proteins such as Band 3 and RhD protein have a much heavier molecular weight than the 
corresponding gel band in which they were identified, indicating that some truncation has 
occurred.  
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Conversely, proteins, such as hemoglobin subunits have a lighter molecular weight than the 
corresponding gel band in which they were identified. It is consistent with the fact that 
hemoglobin tends to be crosslinked to cytoskeleton proteins, especially under stress 
conditions. Following the observation that EMPs proteins were not necessarily found at the 
right position on a 1D gel, and thus that some important protein processing occurred at the 
EMPs level, separation of the EMPs proteome was undertook by two-dimensional gel 
electrophoresis (2D-GE) so as to be able to analyze differentially processed proteins. 
Unfortunately, 2D-GE is poorly amenable to the analysis of membrane and hydrophobic 
proteins. Hence following the work about membrane proteins solubilization for 2D-GE by 
Rabilloud et al, EMP pellets were solubilized in urea, thiourea, DTE, pharmalyte and 
detergent (either CHAPS, ASB-14 or Brij 35). The most abundant protein of EMPs is 
hemoglobin as in RBCs. The presence of this highly abundant protein poses a dynamic range 
problem for proteomic analysis. Consequently, OFFGEL fractionator was used for 
hemoglobin depletion allowing resolving more sport on gel compared to unfractionned 
sample.   
Among the numerous comparisons of EMP protein samples, one of the most relevant results 
was between samples of EMPs stimulated by calcium Ionophore and EMPs that are naturally 
released during ECs storage. Indeed, a certain number of proteins were over expressed in  
calcium Ionophore stimulated EMPs (Fig 4). Spots of interest were excised for subsequent 
protein identification by LC-MS/MS. All identified proteins were involved in calcium 
metabolism, such as for example Sorcin, Alpha-synuclein, Annexin V or Grancalcin. Those 
presented results are preliminary. Data analysis of those results and complementary 
experiments are still in process.       
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Figure 4: Comparison by 2 D-GE between two samples of EMPs, (A) stimulated by calcium 
ionophore and (B) unstiumated  (”naturally” released during storage) 
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Microscopy  
Observation of EMPs by microscopy gave information about their size and shape. By 
confocale differential interference microscopy, it is possible to observe forming EMPs from 
spicules of spheroechinocyte (Fig 5A). Electron microscopy allows observing that EMPs 
tends to aggregate and that they are homogeneous in size (Fig 5B and 5C).  
 
 
Figure 5: Various picture of EMPs using different microscopy technique  
 
(A) Confocal microscopy, magnification of 1500 x. EMPs formation from spicules. (B) 
Scanning electron microscopy, magnification of 4000 x, EMPs surrounding an erythrocyte 
(C) Transmission electron microscopy, magnification 37‟000x. Membrane bilayer of EMPs is 
visible.  
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Coagulation  
In order to verify whether EMPs play a role in transfusion medicine, it has been decided to 
examine if they could take part in coagulation process. As EMPs present negatively charged 
phospholipids on their membranes, they could indeed provide supplementary membranes 
required for the assembly of coagulation complexes such as tenase or prothrombinase.  
 
Flow cytometry also confirmed that there is no more platelet and almost no more MPs in three 
times centrifuged plasma (data not shown).Plasma prepared for calibrated automated 
thrombogram (CAT) experiment always contained 1.6 µM corn trypsin inhibitor (CTI), an 
inhibitor of intrinsic coagulation pathway. In plasma sample without CTI, thrombin 
generation (TG) is sometimes observed, typically in one on three assays with a great 
variability in lag time. This is due to in vitro intrinsic coagulation pathway activation [77]. In 
plasma alone containing 1.6 µM CTI, no TG was observed. 
 
Contribution of EMP phospholipids to support TG 
Contribution of EMP phospholipids in TG was evaluated in a CAT, using PRP-reagent 
containing TF to trigger TG, but few phospholipids. EMPs at different concentrations (from 0 
to 20‟000 EMPs / µl) were added to pooled plasma to test if EMP membranes could amplify 
or generate thrombin in the assay. Results demonstrate that the more EMPs are added to 
plasma,  the greater and faster was TG.  In addition, there was no significant TG in plasma 
without EMPs (Fig 6).  
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Figure 6: Effect of negatively charged membranes of EMPs on TG 
 
Measurement of the procoagulant activity of EMPs using thrombin generation assays (Test 
with PRP reagent, TF is added to trigger reaction). In the presented thrombogram, thrombin 
generation curves are the mean of five independent measures (N=5). 
TG was observed when EMPs where added to plasma at a final concentration of 1000 
EMPs/µl, 10‟000 EMPs/µl and 20‟000 EMPs/µl. The more there are EMPs, the stronger and 
faster is the TG. In the absence of EMPs in plasma, no significant TG was observed, 0 
EMPs/µl.    
 
Contribution of EMPs to trigger TG 
In another assay with MP-reagent, it has been tested if EMPs not only support coagulation 
exposing their negative phospholipids, but also launch coagulation. MP-reagent do not 
contain any TF, no exogenous is added. TG was observed when from 5000 EMPs/µl to 
20‟000 EMPs/µl were added to plasma (Fig 7). It is of importance to note that in plasma with 
1000 EMPs/µl, no TG was observed (Fig 7). Thus, without addition of exogenous TF, there is 
TG in plasma with more than 1000 EMPs/µl EMPs. As positive control, EMPs-coated with 
TF (EMPs-TF) were used in the assay. TG with EMPs-TF was always stronger comparing to 
EMPs. Additionally, the amount of EMPs-TF needed to generate thrombin is logically much 
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smaller than with only EMPs. Indeed, while TF leads TG in EMPs-TF sample, another 
mechanism is involved to trigger TG with EMPs in plasma.    
 
Figure 7: Endogenous Thrombin Potential of EMPs and EMPs-TF at various concentrations. 
 
ETP (nM.min) measurements of plasma samples containing 1.6 µM of corn trypsin inhibitor 
with the addition of 0 to 20‟000 EMPs/µl or 0 to 10‟000 EMPs-TF/µl in thrombin generation 
assays with MP-reagent. Each dots represent the mean of five independent measures ± SD, 
N=5.  
 
As positive control, plasma samples with thromboplastin, here Innovin (Siemens Healthcare 
Diagnostics, Marburg, Germany) or with EMPs-TF were tested. For both, rapid TG with a 
high ETP was observed (Fig 8). Efficiency of anti-human TF was tested in plasma samples 
containing Innovin or EMPs-TF. When Anti-human TF antibody was added to those samples, 
a partial inhibition of TG was observed in the sample with EMPs-TF whereas total inhibition 
was observed in the sample with Innovin (Fig 8). These results also show that EMPs-TF are 
strong activator of TG and have a “thromboplastin-like effect”.   
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Figure 8:  Contribution of EMPs to trigger TG 
Measurement of the procoagulant activity of various samples using thrombin generation 
assays (Test with MP-reagent, no addition of TF). In the presented thrombogram, thrombin 
generation curves are the mean of five independent measures (N=5). No TG was observed in 
plasma alone. EMPs or EMPs-TF are added to plasma at a final concentration of 10‟000 per 
microliter. Plasma with EMPs-TF or Innovin in the absence of EMPs are strong activator of 
thrombin generation in the test. Thrombin generation was also observed in plasma sample 
with EMPs A partial inhibition of thrombin generation was observed when anti-TF is added to 
EMPs-TF sample, whereas inhibition was complete when anti-TF was added to plasma with 
Innovin in the absence of EMPs.  
 
Intrinsic coagulation pathway is inhibited by CTI, anti-human TF was employed to inhibit 
putative plasma TF or EMPs bearing TF even if no TF was evidenced in those samples. 
Additionally, no TF was identified in an extensive proteome study of EMPs [3]. In this way, 
both coagulation pathway triggers are inhibited. Interestingly, TG was not inhibited when 
EMPs were added to plasma containing anti-human TF at a concentration of 1:10 (Fig 9).  
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Figure 9 : Contribution of EMPs to trigger TG 
 
Measurement of the procoagulant activity EMPs in plasma, with and without the addition of 
anti-human TF. (Test with MP-reagent, no addition of TF). In the presented thrombogram, 
thrombin generation curves are the mean of five independent measures (N=5). Final 
concentration of EMPs is 10‟000 per microliter. No TG was observed in plasma alone. In both 
sample, TG was observed. Surprisingly, the generation was stronger and the lag time shorter 
in the presence of anti-human TF.   
 
EMPs were not only capable to support coagulation providing negatively charged 
phospholipids but also are capable to trigger thrombin generation in the assays. In summary, 
we provide evidence that EMPs in plasma are able to induce generation of thrombin, and that 
this generation is not abolished using anti-TF. Thrombin generation is enhanced by adding 
EMPs previously incubated with TF, with an activity similar to that observed with 
thromboplastin.   
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Discussion and perspectives  
 
The increasing interest in MPs lies in the fact that, as they circulate in blood flow, they could 
constitute hallmarks of cellular activation or damage. Consequently, there are always more 
studies on MPs, mainly dealing with platelets or white blood cells derived MPs, erythrocyte 
derived MPs remaining less studied. Therefore new efficient methods have to be developed 
with the aim to obtain qualitative or/and quantitative data on MPs.  
 
The present thesis gave an extensive work to characterize those EMPs using various 
approaches, and demonstrate that those bioactive EMPs not only accumulate in red cells 
concentrate during storage, but they also could be implicated in coagulation processes in an 
active way. EMPs also bear blood group antigens on their surfaces. However, it is not known 
whether they are able to elicit an immune response. In addition, EMP protein contents change 
according to the stimulus, suggesting that there are potentially different kinds of EMPs with 
different function. Finally, microscopy gave information about formation and shapes of 
EMPs.        
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Standardization methods 
In this work, we provide a semi-quantitative counting method of EMPs using flow cytometry. 
It is important to note that there is no standardized method to analyze or to count MPs [61]. 
For that reason, comparison among different studies is particularly difficult.  Yet, since 2005, 
the vascular biology group within the Scientific Subcommittees of the Scientific and 
Standardization Committee (SSC) of the International Society on Thrombosis and 
Haemostasis (ISTH) has proposed to create an international workshop by using calibrated 
microbeads to clarify confusing data regarding MPs numeration, and the first step will be to 
establish a normal range for MPs. This comity also proposed to standardize analysis methods 
of MPs lipids or protein. To our knowledge, until now no consensus has been established to 
provide a standardized method of to count MPs 
Counting Methods 
Our developed counting method is also adapted to quantify MPs from various origins, using 
corresponding antibody.  For example, in platelet rich plasma (PRP), we observed typically 
around 2000 platelet- derived MPs /µl and 100 EMPs /µl (Fig 10). Those results correspond to 
those founded in scientific literature [15, 83]. 
Figure 10 : Flow cytometry analysis of platelet riche plasma  
 
 
 
 
 
A.General flow cytometry windows of a platelet rich plasma sample. Events are sorted according to their 
size and shape. Three different regions are delimited namely microparticles, platelets and counting beads. 
B. Events of MPs region according to their fluorescence with an anti-human erythrocyte antibody. M2 area 
shows the number of positively labeled MPs. C. Event of MPs region according to their fluorescence with 
an anti-human platelet antibody.  M2 area shows the number of positively labeled MPs. 
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Considering that MPs in PRP reflects the number of MPs in blood flow, it could be of great 
interest to count MPs in plasma of patient suffering of various diseases comparing to a healthy 
individual baseline. Another perspective would be to count EMPs from patients (in cardiac 
surgery) before and after surgery/transfusion in order to observe whether an increase in 
number of EMPs is apparent or not. It would be also very interesting to verify if the number 
of EMPs or MPs rise in blood passed through a “cell Saver” machine. Those proposed 
experiments could help to clarify the process of formation and the role of EMPs in transfusion 
medicine.   
 
Proteins 
Interesting results were obtained comparing protein profile of erythrocyte membranes and 
EMPs. As 1 D-GE profiles were slightly different, it indicated some proteins are enriched in a 
sample comparing to another. Western blot confirmed those result, demonstrating that protein 
sorting occurs in process of EMPs formation and release.     
2 D-GE analyses was proceeded to compare various storage conditions or different samples of 
EMPs. As shown in figure 5, it has been observed that some proteins were overexpressed in 
EMPs stimulated by calcium ionophore comparing to EMPs naturally released during storage. 
Subsequent mass spectrometry analysis identified overexpressed proteins involved in calcium 
metabolism.  
This observation is of particular importance, it indicates that protein sorting occurs during the 
formation and release process of EMPs and thus that they are potentially different kinds of 
EMPs. According to the stimulus, those EMPs might be involved in different biological 
processes.   
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Coagulation 
ETP reflects a measure of global coagulation in a sample. It has been demonstrated that EMPs 
could support coagulation, and trigger thrombin generation in plasma when they reach a 
concentration between 1000 and 5000 EMPs/µl, in the absence of triggers of coagulation. So, 
as FXIIa or TF are not present or inhibited, it could be inferred that EMPs have the capacity to 
trigger TG by a mechanism that appears independent of both intrinsic and extrinsic 
coagulation pathways.   
It might be suggested that the “microparticles coagulation pathway” proposed by Furie et al 
trigger TG [52]. Another hypothesis would be that EMPs carry a cryptic form of TF or that 
EMPs are able to activate cryptic TF in plasma [57, 81]. As time preceding the thrombin burst 
or lag-time variations are usually relatively wide when testing intrinsic coagulation pathway 
in vitro [77]. Therefore it could by hypothesized that EMPs might support or imitate intrinsic 
coagulation pathway. It has been demonstrated that factor XI could be activate by thrombin in 
a factor XII independent manner. Thus, EMPs could generate subnanomolar amount of 
thrombin sufficient to activate factor XI resulting in the observed thrombin explosion in CAT 
[77, 82] (This process is also called “Josso loop” in coagulation). In future experiment, the 
use of a factor XI inhibitor would be interesting to determine if it is involved in TG with 
EMPs.     
An unexplained observation have been done comparing sample of EMPs with and without TF 
inhibitor. Expected results were either no significant difference or (partial) inhibition of TG in 
the case of putative presence of TF on EMPs. Curiously, it has been observed that in sample 
with TF inhibitor, lag time was reduced and ETP was higher (Fig 9). Even if TF inhibitor does 
not fully inhibit TF, it has been demonstrated that this last was very efficient to inhibit TF of 
thromboplastin and quite efficient on EMPs bearing TF. It might be also supposed that this 
 186 
observation is due to an in vitro artefact (but reproducible). In order to understand this 
unexpected result, it might be of great interest to test plasma and EMPs sample with FVIIa 
inhibitors instead TF inhibitor, however this last is not commercially available. 
Numerous factors are involved in hemostasis, all having multiple roles in this carefully 
regulated process. Coagulation pathways are thus interdependent. In this field, EMPs are also 
a player whose role is not yet clearly define. Due to the fact that in case of injury, thrombin is 
also linked to inflammation [88], the TG observed by EMPs might support inflammation 
instead of coagulation as observed, this relevant hypothesis has also to be taken into account.   
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Final remarks 
 
This thesis provides evidences that storage of RBCs is associated with the generation of 
EMPs. Those EMPs bear blood group antigen and are different according to the stimulus. In 
addition, coagulation assays demonstrate that EMPs support and could trigger TG under 
certain circumstances. This supports the hypothesis that among MPs, EMPs are also bioactive. 
Even if no clinical study on the involvement of EMPs in coagulation has been conducted yet, 
their presence in ECs is totally innocuous. As numerous studies suggest that there is a link 
between transfusion complication and storage time of ECs, we suggest that EMPs could be 
mediators of those complications under certain circumstances.  
  
The role and implication of EMPs in biological processes are far from being entirely 
understood. There are numerous scopes on EMPs research, as mentioned. Therefore the need 
of investigations in various fields has to be done on MPs and specifically EMPs in order to 
allow increasing global knowledge on blood and blood products.   
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